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The association of cardiovascular risk factors including hypertension, diabetes,
cholesterol, kidney function, and arterial stiffness with cognitive impairment in older
adults is a well-studied phenomenon. However, there is considerably less evidence
relating cardiovascular health specifically to a diagnosis of Mild Cognitive Impairment
(MCI). As a precursor state of dementia, MCI is characterized by a decline in cognitive
function from previous level, but not to the degree that activities of daily living are
impaired. Not everyone who is diagnosed with MCI will eventually transition to
dementia, but the transition rates are much higher compared to the general population
(5-15% per year compared to 1-2%). The primary aim of the current investigation is to
examine the relationship between individual cardiovascular risk factors and 5-year
incident MCI risk and to investigate whether these relationships are moderated by
apolipoprotein E genotype (APOE). An additional primary aim was to investigate
whether an aggregation count of cardiovascular risk factors (MSLS-CVRFS) and two
common cardiovascular risk factor profiles (FRS and ASCVD risk score) were related to
5-year incident MCI risk. Following exclusions for dementia, the study sample included
625 (Average baseline age: 61.98, 61% female) participants from the 6th and 7th waves

of the Maine-Syracuse Longitudinal Study (MSLS). MCI diagnosis was made by a team
of three investigators applying established MCI diagnostic criteria, with 96 participants
diagnosed with possible MCI. Multiple logistic regression analysis was used to examine
the association between individual baseline cardiovascular risk factors (SBP, TC, HDL,
LDL, TRIG, GFR, THCY, Diabetes, PWV) and MCI with adjustment for basic
demographic covariates including age, sex, years of education, and ethnicity. The same
method was used for determining APOE interaction effects and relating cardiovascular
risk factor scores (CVRFS, FRS, ASCVD) with MCI risk. Among individual risk factors,
higher GFR and HDL were associated with lower MCI risk, while diabetes was
associated with higher MCI risk. No APOE interaction effects were observed. All three
of the cardiovascular risk factor scores tested were associated with higher MCI risk.
These findings have clinical implications with regard to predicting MCI risk with a
combination of cardiovascular risk factors. While these factors have previously been
related to continuously distributed cognitive performance measures, it is critical that
their relationship to a clinically defined binary outcome like MCI be investigated because
treatment decisions are based on diagnosis.
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1. INTRODUCTION
1.1. Normal Cognitive Aging
Cognitive changes with age are an expected component of the human lifespan.
Therefore, it can be difficult to distinguish the pattern of change that can be considered
“normal” from what can be considered abnormal or pathological in nature. The cognitive
and functional deficiencies associated with dementia, be it Alzheimer’s disease (AD) or
Vascular Dementia (VaD), are obvious in comparison to a healthy older adult, but as
efforts against dementia are increasingly directed towards preventing impairment in the
first place this comparison is not as helpful anymore. It has become necessary to
identify cognitive impairment of a pathological nature before extensive functional loss,
and the concept of Mild Cognitive Impairment (MCI) has arisen to accomplish this. In
order to investigate MCI, it is important to understand the type and degree of cognitive
change that one can expect in a healthy, cognitively normal (CN) older adult.
The concept of crystallized vs fluid intelligence is often a featured component of
what constitutes normal cognitive aging. Crystallized intelligence refers to long term
memory related abilities including vocabulary, knowledge, and occupational expertise.
Fluid intelligence relates more to short term and working memory related abilities
including novel problem solving, information processing, and psychomotor abilities
(Harada, Love, & Triebel, 2013; Anstey & Low, 2004). This distinction is often used to
summarize normal cognitive aging as fluid intelligence is thought to peak around mid30s whereas crystallized intelligence is thought to steadily increase throughout the
lifespan into the 70s (Salthouse, 2012). While helpful, this distinction is somewhat
simplistic, and the pattern of cognitive decline associated with successful aging free
1

from pathology is more complex and dependent on additional factors besides age
alone.
Going beyond a simple distinction of crystallized vs fluid intelligence, a variety of
changes are seen in cognition in normal aging. For declarative memory, episodic
memory is expected to decline with age while semantic memory persists into late life
(Rönnlund, Nyberg, Bäckman, & Nilsson, 2005). However, non-declarative memory,
including procedural memory, remains largely unchanged across the lifespan (Lezak,
Howieson, Bigler, & Tranel, 2012). These memory changes are consistent with other
studies that have found acquisition (the ability to encode new information) and retrieval
of recently learned information decline with age (Haaland, Price, & Larue, 2003; Harada
et al., 2013; Price, Said, & Haaland, 2004) whereas retention of successfully learned
information in long term memory is maintained (Whiting & Smith, 1997). Likewise, it is
normal for older adults to decline in tasks involving selective and divided attention,
although with simple attention tasks no impairment is seen (Salthouse, Fristoe,
Lineweaver, & Coon, 1995). Reductions in processing speed and executive function are
also normal, with older adults performing worse at tasks involving mental flexibility,
response inhibition, inductive reasoning, and abstraction (Lezak et al., 2012; SinghManoux et al., 2012; Wecker, Kramer, Hallam, & Delis, 2005). A variety of other
cognitive abilities are relatively preserved in normal aging including language skills and
ability to understand similarities and proverbs (Harada et al., 2013). These changes in
cognitive abilities refer to averages, but individual differences still play a large role in
determining whether an individual will experience cognitive decline with age, and what
degree of impairment will occur.
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Often degree of impairment (whether normal or abnormal) is subject to individual
differences in genetics, education, occupation, and culture. These factors, among
others, have been bundled into a concept known as cognitive reserve, and higher
cognitive reserve may be protective against deficits associated with normal aging and
those associated with pathology (Stern, 2002). Education in particular has been
recognized as an influential predictor of cognitive function in several recent normative
value publications, including a study of centenarians who are of particular value to the
study of cognitive aging (Davey et al., 2010; G.A. Dore, Elias, Robbins, Elias, &
Brennan, 2007). Other experimental studies have reported an effect of education on
age related cognitive impairment, but the effect may largely depend on the type of
cognitive ability being measured (Ardila, Ostrosky-Solis, Rosselli, & Gómez, 2000).
In addition to cognitive performance changes there are identifiable structural
brain differences in normal aging vs abnormal cognitive aging that may play a causal
role in observed deficits. For example, hippocampal atrophy is traditionally associated
with AD, but still occurs in normal aging to a much smaller extent (De Leon et al., 1997).
Early studies of structural changes in the aging brain likely overestimated the extent of
neuronal death, with the current thought being that subtle changes involving neuron size
and synaptic plasticity in key cortical areas may relate to cognitive changes (Morrison &
Hof, 1997; Terry & Katzman, 2001; Whalley, Deary, Appleton, & Starr, 2004).
Reductions in gray matter have been reported as early as age in the 20s (Terry &
Katzman, 2001). The concept of cognitive reserve is supported with structural evidence
as well, suggesting it may contribute to neural plasticity, larger brain size, and reduced
neural activity during cognitive tasks, possibly reflecting more efficient resource usage
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(Solé-Padullés et al., 2009; Whalley et al., 2004). These small structural changes and
subtle loss of general efficiency among key brain circuits are in sharp contrast to the
biological changes seen in dementia (See Section 1.3.3.). For further reading regarding
cognitive aging and accompanying structural changes consult the following resources
(Park, Denise c.; Reuter-Lorenz, 2012; Raz & Rodrigue, 2006; Salthouse, 1991).
Ultimately, separating normal cognitive aging from pathological cognitive
changes can be difficult. However, the changes observed with normal aging are not
comparable to pathological conditions such as dementia, which includes crippling
deficiencies in cognitive function and ability to perform activities of daily living (ADLs).
Normal changes in cognitive function do not compare to even mild degrees of dementia
(Erkinjuntti, Laaksonen, Sulkava, Syrjalainen, & Palo, 1986). While there are cognitive
deficits seen in normal cognitive aging, they are of a minor degree and not enough to
interfere with daily function or social involvement. The idea of pathology with respect to
cognitive aging should be based on the degree to which the changes interfere with an
individual’s ability to function independently. However, in terms of dementia this
introduces a problem. With treatment for dementia increasingly focused on identifying
prodromal states, it has become necessary to distinguish normal cognitive aging from
abnormal aging without relying on overt functional impairment in an effort to diagnosis
and label this prodromal condition. The clinically defined concept of MCI has arisen to
achieve this, and it represents a likely transitional phase between normal cognition and
dementia. This pathway between CN, MCI, and Dementia does not exist on the normal
continuum for cognitive changes with advancing age but rather represents a separate
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pathway of pathological changes far exceeding those seen in normal aging (See Figure
1.).

Figure 1. Time Course of Dementia with Preclinical MCI Phase
Note. While some decline in cognitive function is expected with increasing
age, the changes seen in MCI/Dementia pathology are of a much more
significant degree. (Sperling et al., 2011)

It is of chief epidemiological importance to determine what factors might influence
whether an individual remains CN with advancing age or diverges to a more sinister
degree of cognitive impairment, potentially indicative of underlying dementia pathology.
The current study is focused on the role of cardiovascular risk factors in this divergence
by focusing on MCI risk. The rationale for this objective is based on the overwhelming
evidence that cardiovascular risk factors are associated with cognitive performance in
older age. Therefore, before discussing the conditions of dementia and MCI, and how
they may relate to cardiovascular health, in the next section we will summarize findings
suggesting an association between cardiovascular risk factors and cognition assessed
on a continuum.
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1.2. Cardiovascular Risk Factors and Cognitive Functioning
1.2.1. Hypertension
The relationship between blood pressure and cognitive functioning has been
studied extensively, often with conflicting results until the latter half of the 20th century.
At this time, longitudinal studies began to consistently present evidence associating
high blood pressure at mid-life with a decline of cognitive functioning in older age (M.F.
Elias, Goodell, & Dore, 2012; M.F. Elias, Wolf, D’Agostino, Cobb, & White, 1993; Wilkie
& Eisdorfer, 1971). More recent studies have specifically shown an association between
elevated midlife blood pressure and increased risk of dementia (Alonso et al., 2009;
Korf, White, Scheltens, & Launer, 2004; Qiu, Winblad, & Fratiglioni, 2005).
1.2.2. Arterial Stiffness
Arteriosclerosis is the progressive hardening of arteries due to age or
pathological processes such as plaque buildup along the arterial wall (atherosclerosis).
Compliant arteries are necessary for optimal hemodynamics, allowing the heart to
supply the body with oxygenated blood with as little impetus as possible (Berne & Levy,
1986). Stiff arteries reduce this efficiency and create strain on the heart and peripheral
capillary beds, as well as increasing the risk of thrombosis, emboli, and infarction.
Severe atherosclerosis is associated with an increased dementia risk and may be
exacerbated by the Apolipoprotein E ε4 (APOE) allele, discussed further in Section
1.2.7 (Hofman et al., 1997; Laurin, Masaki, White, & Launer, 2007; van Oijen et al.,
2007). Pulse Wave Velocity (PWV; meters/second) is a recently developed indirect
measure of arterial stiffness using applanation tonometry that measures the speed of
the pressure wave generated by heart systole as it travels to the periphery and is
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reflected back. Several recent studies have associated increased PWV (which reflects
stiffer arteries) with a decrease in cognitive functioning (M.F. Elias et al., 2009; Wendell,
Zonderman, Metter, Najjar, & Waldstein, 2009).
1.2.3. Homocysteine
Homocysteine is an amino acid normally metabolized by methionine and is
measured in plasma total homocysteine (tHcy; μmol/L). A high level of tHcy, known as
hyperhomocysteinemia (HHcy) can cause endothelial cell damage and inflammation,
gradually deteriorating or hardening blood vessel walls in an arteriosclerotic process
(Obeid & Herrmann, 2006). Homocysteine levels are heavily influenced by diet choices,
and diets low in vitamin B6, vitamin B12, folic acid and high in methionine (animal
proteins) are risk factors for HHcy, as is older age and male sex (Kalra, 2004). The
inflammatory properties of homocysteine form the basis for the pathology of HHcy as it
pertains to brain health and dementia. Homocysteine promotes neuronal degeneration,
particularly of white matter, a consistent target of cerebrovascular pathologies (Obeid &
Herrmann, 2006). Results from the Framingham Heart Study suggest that individuals
with a tHcy level over 14 μmol/L have twice the risk of developing Alzheimer’s disease,
and associate HHcy with smaller brain volume and silent infarctions (Seshadri et al.,
2002, 2008). Numerous other studies have associated elevated levels of tHcy with
increased dementia risk (Ho et al., 2011; van Dam & van Gool, 2009; Wald,
Kasturiratne, & Simmonds, 2011).
1.2.4. Cholesterol
The relationship between cognitive function and serum lipid levels including Total
Cholesterol (TC; mmHg), High density lipoprotein (HDL; mmHg), Low density
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lipoprotein, (LDL; mmHg), and triglycerides (TRIG; mmHg) is controversial. Many
studies have positively associated TC with cognitive function while others have found a
negative association. HDL is considered to be a positive factor, whereas TRIG is
considered to be a negative factor, but results are mixed on these lipid levels as well.
For a full review of this topic consult (Muldoon & Conklin, 2014).
1.2.5. Diabetes
Diabetes mellitus is a significant risk factor for cognitive impairment, and has
several common cardiovascular comorbidities which can also impair performance
(Awad, Gagnon, & Messier, 2004; Rodstein, 2001). Commonly affected cognitive
abilities include attention, memory, processing speed, and executive functioning (Kodl &
Seaquist, 2008). Further reading on this extensively studied topic is available in several
recent reviews (Biessels, Deary, & Ryan, 2008; Brands, van den Berg, Biessels, &
Kessels, 2014).
1.2.6. Renal Function
Renal function is a reflection of kidney health and can be represented
numerically by glomerular filtration rate (GFR), the rate of blood flow through the kidney.
GFR is estimated through various formulae usually including serum creatinine (a
metabolic byproduct removed from the blood by the kidneys), age, sex, ethnicity, height,
and weight. A sustained GFR of less than 60 mL/min is usually a cut-off associated with
chronic kidney disease (CKD), which has been negatively associated with cognitive
function in early and late stages of CKD (Brady et al., 2009; Elias et al., 2009). Kidney
function is usually dichotomized into CKD or non-CKD based on GFR cut-offs when
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studied in association with cognitive function (Buchman et al., 2009; Elias et al., 2009;
Kurella-tamura et al., 2009).
1.2.7. Apolipoprotein E Genotype
Apolipoprotein E (APOE) is a metabolic protein linked to cognitive impairment
based on the alleles of the corresponding chromosome 19 gene APOE. Specifically, the
presence of at least one ε4 allele (APOE ε4 carrier) is a risk factor for cardiovascular
disease, dementia, and impaired cognitive function (Farrer et al., 1997; Small, Rosnick,
Fratiglioni, & Bäckman, 2004). APOE ε4 carrier status has also been shown to interact
with other risk factors, including diabetes, potentially exacerbating cognitive impairment
(G. A. Dore, Elias, Robbins, Elias, & Nagy, 2009; M. N. Haan, Shemanski, Jagust,
Manolio, & Kuller, 1999). Aside from considering APOE genotype a risk factor for
cognitive impairment, its interaction with other cardiovascular risk factors needs to be
considered.
1.3. Dementia
1.3.1. Overview
Dementia can refer to a large number of debilitating diseases that can
compromise an individual’s cognitive functioning, personality, social functioning, and
ability to live independently. It is a highly heterogeneous condition resulting from several
different pathologies, and most often combinations of pathologies. While the most
common form is presumed to be Alzheimer’s disease (AD), other forms include
Vascular Dementia (VaD), Dementia with Lewy Bodies (DLB), Frontotemporal Dementia
(FTD). Dementia can be accompanied by a variety of comorbidities including
Parkinson’s disease and Huntington’s disease. As worldwide life expectancies get
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longer, these aging-related diseases have been increasing in prevalence and are
quickly becoming a leading healthcare crisis in the 21st century. Almost 50 million
people worldwide are estimated to have some form of dementia, with a projected 8
million new cases each year (World Health Organization). In 2010 worldwide dementia
costs were estimated to be $604 billion, about 1% of world gross domestic product, an
enormous cost considering prevalence rates are expected to triple by 2050 (World
Health Organization). This increase in dementia prevalence will have devastating social
and economic repercussions, and considering the lack of effective treatment or
prevention techniques requires immediate attention as a worldwide research priority.
1.3.2. Diagnosis
Diagnosing dementia usually involves detecting a clinically significant decline in
cognitive function from a previous level, to the extent that the patient can no longer
function independently or perform activities of daily living (ADLs; getting dressed,
personal hygiene, going shopping etc.). While episodic memory impairment is a
common cognitive deficit, particularly in the early stages of AD, other deficits in
cognitive domains including language, attention, executive functioning, working
memory, and visual-spatial reasoning are possible. Biomarkers and neuropathology are
becoming an increasingly important part of any dementia diagnosis, taking into account
the variety of etiologies responsible for the condition. For example, detection of amyloid
markers in the brain or cerebrospinal fluid (CSF) is now an important diagnostic aspect
of AD, while cerebrovascular disease or the presence of cerebrovascular risk factors is
a required part of most VaD diagnoses. Other dementia pathologies such as DLB and
FTD are different and can result in various clinical phenotypes, but will not be discussed
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in this study. Mixed etiologies are probably the most common cause of dementia, as
vascular insults and vascular cascade have been shown to accompany AD pathology,
resulting in patients exhibiting deficits characteristic of both AD and VaD (Jellinger &
Attems, 2007; D. S. Knopman, 2006).
1.3.3. Pathology
1.3.3.1. Alzheimer’s Pathology
Alzheimer’s pathology is relatively well documented and consistent across cases
with a general worsening of symptoms and pathology from onset until death. The two
hallmark signs of the disease are intracellular neurofibrillary tangles composed of
hyperphosphorylated tau protein (a microtubule associated protein) and extracellular
neuritic plaques formed by depositions of beta amyloid (Aβ). Neuronal atrophy is also
common, particularly in the medial and temporal lobes, including the hippocampus.
These regions are often the first affected by AD pathology and are likely associated with
primary memory deficits in AD patients. As the disease progresses these pathologies
can spread to other regions such as the frontal cortex, and cognitive functioning
progressively worsens as a result of widespread synaptic death.
While a causal role for any of these biomarkers has yet to be established, their
presence has become an integral factor in the diagnosis of AD, particularly amyloid
plaques, which are required for diagnosis. Traditionally this has resulted in tiers of AD
diagnosis denoted as possible, probable, and definite, the latter only possible with postmortem evidence of AD pathology at autopsy. However, improved AD biomarker
detection via neuroimaging and spinal taps for cerebrospinal fluid (CSF) have aided premortem diagnoses. Magnetic-Resonance-Imaging (MRI) is useful for detecting areas of
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structural atrophy. Positron emission tomography (PET) has proven invaluable in the
detection of AD brain pathology. PET scans using Pittsburgh compound B (PiB) reliably
detect amyloid plaque deposits in a full brain scan. Fluorodeoxyglucose (FDG) PET
scans assess glucose metabolism across the brain, and can be used to check for
hypometabolism in certain areas, particularly the medial and temporal lobes when
assessing AD pathology.
1.3.3.2. Vascular Pathology
Vascular Dementia pathology is considerably more heterogeneous than AD
pathology because it can be caused by any combination of cerebrovascular diseases
with varying severity. Consequently, symptoms and prognosis can be more varied
depending on the location and severity of the vascular insult. Stroke is perhaps the most
obvious cerebrovascular event that could contribute to cognitive impairments of a
dementia degree. However, other smaller vessel diseases are possible and over time
can be just as impactful. Small vessel diseases are estimated to have a causal role in
40-70% of VaD cases (Román, 2003). These include lacunar infarctions (which are
often asymptomatic), cerebral microbleeds, and leukoaraiosis. Small infarctions are
localized tissue death due to an obstruction of normal blood flow to the area and are not
necessarily uncommon. The prevalence of silent infarctions is about 20% in the normal
population but as high as 50% in those with vascular disease (Longstreth et al., 2005).
Silent infarctions are associated with a doubled risk of vascular cognitive impairment or
dementia over a five year period (Longstreth et al., 2005). Leukoaraiosis is represented
by white matter hyperintensities (WMH) on T2 weighted MRI images demonstrating the
destruction of white matter tracts in the brain. This white matter damage is thought to be
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associated with vascular mechanisms and is associated with typical cardiovascular risk
factors including hypertension and diabetes, and may play a causal role in cognitive
deficits seen in VaD.
1.3.3.3. Mixed Pathology
Dementia and MCI rarely fit into neat diagnostic paradigms perfectly describing
the underlying pathology. The prevalence of mixed pathology both in dementia and MCI
has been increasingly recognized, with some studies claiming a mix of AD and vascular
pathology may account for the near-majority of dementia cases at around 40% (Price,
Nguyen, Lamar, & Libon 2015; Lockhart and DeCarli 2015). VaD and AD pathology
have considerable co-occurrence, with some going so far as to claim “Pure VaD” and
“Pure AD” as rare (Jellinger & Attems, 2007). There is often a vascular component to
AD, and unfortunately the two pathologies have a “complementary and synergistic
relationship in the genesis of cognitive impairment” (D. S. Knopman, 2006). Growing
evidence suggests that AD and vascular pathology may be additive in that individuals
with mild AD or cerebrovascular pathology are less likely to progress to dementia than
individuals with both (Fotuhi, Hachinski, & Whitehouse, 2009; Nagy et al., 1997;
Schneider, Arvanitakis, Bang, & Bennett, 2007; Snowdon et al., 1997; Viswanathan,
Rocca, & Tzourio, 2009).
The degree to which dementia varies in terms of mixed etiologies is not
surprising considering that AD and VaD share several common risk factors, including
cardiovascular risk factors. Mixed pathologies complicate differential dementia
diagnosis because the brain areas effected can vary considerably from the common
parietal-temporal damage seen in AD to the subcortical white matter damage often

13

observed in VaD. This may be the case for MCI diagnosis as well if this condition truly
reflects early stages of the pathology seen in fully developed dementia. Cardiovascular
risk factors may contribute to both AD and VaD pathology and both of these etiologies
need to be considered when discussing preventive interventions and post-diagnosis
treatments.
1.3.4. Prodromal State
Current efforts regarding the treatment of dementia are increasingly focused on
prevention. This emphasis has resulted in increased attention to identifying prodromal
states of dementia. While many states have been proposed and defined, the concept of
MCI has emerged as an important clinical state in the progression of dementia
pathology. MCI is an age associated decline in cognitive functioning from normal levels
that does not meet thresholds for dementia diagnosis, nor impair the individual’s daily
functioning. While diagnoses and operational definitions for MCI vary, all agree that MCI
is a clinically relevant category of cognition that represents a risk factor for progression
to dementia. Identifying individuals presenting with MCI provides an opportunity for early
preventative interventions to slow the progression to dementia or ideally stop it
altogether, though a delay in transfer from MCI to dementia is the most realistic
treatment outcome at this time. MCI will be discussed fully in the following section.
While this study does not deal with intervention it does deal with MCI as primary
cognitive outcome variable.
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1.4. Mild Cognitive Impairment
1.4.1. Conceptual Overview
MCI is a continually developing clinical concept intended to represent a
transitional period between normal cognitive functioning with age and dementia states.
Figure 1. illustrates this concept as a transitional period between normal function and
dementia, with a preclinical period predating the onset of MCI (Sperling et al., 2011).
The concept originates from early longitudinal studies on aging and dementia, in which
large groups of subjects appeared to fit in intermediate stages that could not be defined
as normal or demented (Petersen, 2004). From a modern perspective this degree of
impairment was originally defined as an intermediate stage of impairment based on the
Global Deterioration Scale (Reisberg, Ferris, De Leon, & Crook, 1988). From this point,
the concept has evolved under several names including benign senescence
forgetfulness, age-associated memory impairment (AAMI), age-associated cognitive
decline (AACD) and cognitive impairment no Dementia (CIND), although there has been
considerable overlap between all of these systems of description and diagnosis (R. C.
Petersen, 2004). The important and widely agreed upon characteristics of MCI are as
follows: 1.) Person has an impairment in one or more cognitive domains that reflects a
decline from previous function, 2.) Person has largely preserved independence and
every day functioning and can perform activities of daily living (ADL) with little to no
assistance, 3.) Person is not demented. How these characteristics are defined and
measured, in addition to whether or not requiring corroboration by an informant
(typically a family member), varies considerably. Moreover, meeting criterion two
eliminates the possibility of meeting criterion 3 in most of these systematic approaches.
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MCI represents a subtle continuum between what is considered normal cognitive
aging and pathological impairment due to dementia, and this creates what is referred to
as an ambiguous ‘grey zone’ with considerable overlap on either side of the continuum
(Feldman & Jacova, 2005; Petersen, Smith, & Waring, 1999). See Figure 2. for a
representation of this continuum and note the overlap on both sides of the period
commonly defined as ‘MCI’. The lack of clinical consensus in the field for defining this
period comes from several different sources, including but not limited to varying
diagnostic tools such as cognitive assessment measures, differences in populations
(e.g., community-based samples vs clinic referral samples), and perhaps most of all the
several etiologies and pathology proposed to be behind MCI, which may vary as much
as dementia etiology does (Petersen et al., 2014; Stephan et al., 2012). This has led to
considerable variability in diagnosis and conceptualization of this important clinical
period.
Normal

MCI

Dementia

Worsening Cognitive Performance
Figure 2. Continuum of Cognitive Performance from Normal to MCI to Dementia
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1.4.2. Diagnosis
Diagnostic criteria for MCI have evolved via several nuanced changes and
categorizations over the past two decades, but the fundamental Mayo Clinic criteria laid
out by Petersen et al. in 2004 are still essential. Petersen laid out 5 defining
characteristics of MCI, and while these are adjusted somewhat by other diagnostic
criteria (Diagnostic and Statistical Manual of Mental Disorders V (DSM-V), National
Institute on Aging-Alzheimer’s Association (NIA-AA) etc.) the general principles are
largely the same. These original criteria are outlined in Table 1., along with recent
revised criteria. One may note that these criteria are focused specifically on memory
impairment as this was thought to be the most common form of MCI, and the form most
likely to predict AD (Petersen et al., 2014). These criteria are still relevant today but now
represent a common MCI subtype referred to as Amnestic MCI or a-MCI (Petersen et
al., 2014; Petersen, 2011).
Table 1. Mayo Clinic MCI Criteria Original and Expanded
Original
Revised/
Criteria
Mayo
Expanded
Clinic
Reported Memory Impairment (Self or Informant)
✓
Reported Cognitive Impairment (Self or Informant)
✓
Objective Memory Impairment
✓
(Neuropsychological testing)
Objective Cognitive Impairment
✓
(Neuropsychological testing)
Preserved general cognitive function
✓
Preserved functional independence and ADLs
✓
✓
No dementia
✓
✓

The biggest shift in MCI diagnosis in recent years has been the adoption of
multiple subtypes of MCI to reflect the variety of clinical phenotypes commonly seen.
Diagnostic criteria have accounted for this by specifying the term ‘cognitive impairment’,
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with more sensitivity to type of impairment, primarily involving memory or not. Revised
Mayo criteria, in addition to NIA-AA criteria for MCI and DSM-V criteria for Mild
Neurocognitive Disorder (NCD), now allow for cognitive impairment to reflect any
cognitive domain, not just memory impairment (Petersen et al., 2014; Petersen, 2011).
In recognition that multiple cognitive domains can be impaired in the same case, four
major MCI subtypes have arisen to reflect different cognitive profiles. The four subtypes
reflect two values: whether or not the individual has a memory impairment (amnestic or
non-amnestic) and whether or not the individual has impairment in multiple cognitive
domains (single domain or multi-domain). Therefore the current MCI subtypes are
amnestic MCI single domain, amnestic MCI multi-domain, non-amnestic MCI single
domain, and non-amnestic MCI multi-domain. Reliable prevalence rates for these
subtypes have not been established at this time, though non-amnestic single domain
MCI is considered rare (Petersen, 2004). It is important to recognize that these MCI
subtypes do not reliably represent etiology of the condition and pertain only to clinical
phenotype. The various brain pathologies though to be responsible for MCI and
dementia have not been accurately mapped on to these diagnoses, though there is
growing evidence that amnestic forms of MCI may be associated with AD pathology
whereas non-amnestic forms may represent non-AD dementia pathologies including
cerebrovascular disease (Feldman & Jacova, 2005; R. Petersen, Thomas, & M, 2005;
Stephan et al., 2012).
While the essential aspects of cognitive impairment in MCI are becoming more
established, there is little consensus in the field regarding specific tests or assessments,
as well as corresponding cut-off scores, for use in diagnosing MCI. Larger scale
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neuropsychological batteries provide a detailed cognitive profile of patients, but are not
always practical to use in a clinical setting. Quicker assessments are often used, and
even amongst these there is great variability in the specific tests used. Common
assessments used include the Wechsler Adult Intelligence Scale Revised (WAIS-R),
Wechsler Memory Scale-Revised (WMS-R), The Auditory Verbal Learning Test, The
Wide Range Achievement Test (WRAT), Controlled Oral Word Associations, and the
Boston Naming Test. Shorter assessments include the Mini Mental State Exam (MMSE)
and the Montreal Cognitive Assessment (MOCA), though the MMSE has been criticized
as not being sensitive enough as a single use measure detecting impairment. Studies
often use multiple measures to attempt to detect impairment in multiple domains of
cognitive functioning including memory, executive functioning, attention, language, and
visuospatial ability. While no specific cutoff scores are agreed upon, it is generally
considered that impairments ranging from .5-1.5 standard deviation units below agebased cognitively healthy norms are a good starting point, reflecting performance in the
31st percentile and lower (Petersen, 2003). However, impairment has to be examined
considering previous function of the individual, which is more important than arbitrary
cut-off scores. A change in function is a reliable indicator of possible MCI, and this
approach is often used in epidemiological studies and retrospective analyses.
1.4.3 Prevalence and Incidence
Population statistics for MCI are difficult to determine given the variety of
acceptable diagnostic criteria for clinical deficit or change from a previous level, and the
population from which the individuals were sampled. Early epidemiological studies likely
underestimated the prevalence of MCI in the population because of the memory bias in
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diagnosis (Petersen et al., 2014). When MCI is rightfully conceptualized as including all
forms of cognitive impairment prevalence statistics have been higher. In United States
samples the prevalence of MCI in the 65+ year old population tends to range between
15-25% (Ganguli et al., 2010; O. Lopez, Jagust, & DeKosky, 2003; Manly et al., 2008;
R. Petersen, Roberts, & Knopman, 2010; Plassman, Langa, & Fisher, 2008; Purser,
Fillenbaum, Pieper, & Wallace, 2005). A reliable incidence rate is similarly challenging
but some aggregate data suggests the rate may range between 20-70 per 1000 personyears (Petersen et al., 2014; Ward, Arrighi, Michels, & Cedarbaum, 2012). Despite the
variability in statistics it is clear that MCI is not a rare condition and deserves attention.
1.4.4. Prognosis and Treatment
The clinical relevance of MCI depends on its use as a detection of a prodromal
dementia state that provides the opportunity for early interventions and identification of
at-risk populations. It is important to note that the prodromal state where MCI is first
seen is part of the long latency period for dementia, where pathology is emerging in the
brain but the individual is not yet demented as illustrated in Figure 3. (Sperling et al.,
2011). Regardless of the various definitions and diagnostic procedures, MCI does
reliably predict an increased risk of dementia as compared to normal cognitive aging.
MCI is a risk factor for dementia, as it is now clear that lowered cognitive functioning in
a number of domains predicts dementia many years later. Conversion rates from MCI to
dementia vary, but are reported around 5-15% per year (Larrieu et al., 2002; Petersen
et al., 1999; Petersen, 2011). This rate can be compared to an estimated dementia
conversion rate of 1-2% per year from the general population (Petersen, 2011). Overall,
several longitudinal studies have supported that MCI is a significant risk factor for
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dementia and predicts a higher conversion rate, though not everyone with MCI will end
up progressing to dementia (Busse, Hensel, Guhne, Angermeyer, & Riedel-Heller,
2006a; O. Lopez et al., 2003; Manly et al., 2008; Plassman et al., 2008). Some studies
have shown reversal of MCI patients to cognitively normal levels at a rate as high as
40%, which likely reflects errors related to diagnosis being heavily memory-based in
earlier approaches and the difficulty of separating normal cognitive aging from MCI
(Larrieu et al., 2002).

Figure 3. Neuropathological Cascade Preceding MCI and Dementia
Note. The prodromal phase of dementia is a long and dormant process of which MCI is the
first phase in which cognitive deficits are observable. This example from (Sperling et al.,
2011) provides a hypothetical model of AD pathology predating MCI and Dementia, likely by
many years.

Several factors have been studied predicting higher risk of transitioning from MCI
to dementia. The greater the extent of cognitive impairment of the individual the more
rapid progression to dementia tends to be (Dickerson, Sperling, Hyman, Albert, &
Blacker, 2007; Visser, Verhey, & Knol, 2009). The APOE ε4 allele has also been
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associated with more rapid progression to dementia (Hsiung, Sadovnick, & Feldman,
2004; Mosconi et al., 2004). Neuroimaging has supplemented MCI to dementia
transition risk assessment, but there are conflicting findings. A 2010 study by Jack et al.
revealed that MCI subjects in the bottom 25% of hippocampal volume (revealed by MRI)
for sex and age norms had a more rapid progression to dementia. Other AD biomarkers
and neuropathology have been associated with transition from MCI to AD, including
hypometabolism in the temporal and parietal lobes on FDG-PET scans (Chetelat et al.,
2003; Drzezga, Grimmer, & Rjemenschneider, 2005; Landau, Harvey, & Madison,
2010). Cerebrospinal fluid markers of low beta amyloid peptide 42 and tau protein have
similarly been shown to predict more rapid transition (Hansson et al., 2006), though
amyloid has been found in cognitively healthy adults (DS Knopman, Parisi, & Salviati,
2003). The neuropathology of MCI is not well understood at this time, though there is
some evidence that it may reflect early dementia pathology, which varies widely in
etiology given the several different forms of dementia (Stephan et al., 2012).
Treatment for MCI is currently suboptimal, and pharmacological interventions
have been challenging given the heterogeneity of the condition. At this time there is no
FDA approved treatment for MCI (Petersen, 2011). A few clinical trials have taken place
with largely null results. Donezpil, a cholinesterase inhibitor, failed to reverse cognitive
decline in an MCI population (Russ & Morling, 2012) and similar results were observed
for vitamin E trials (Farina, Isaac, Clark, Rusted, & Tabet, 2012; Petersen et al., 2014).
Cognitive training has shown limited efficacy but may be a promising avenue for further
trials (Jean, Bergeron, Thivierge, & Simard, 2010; Massoud, Belleville, & Bergman,
2007). While modification of cardiovascular risk factors has received mixed results in
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terms of slowing the progression from MCI to Dementia (Di Carlo, Lamassa, &
Baldereschi, 2007), there is some evidence that regular aerobic exercise can slow the
progression significantly (Ahlskog, Geda, Graff-Radford, & Petersen, 2011). Ultimately,
more clinical trials are necessary, ideally those that combine multiple interventions such
as cognitive training, healthy lifestyle changes, and medication that are based on as
much information as possible regarding the etiology of an individual’s MCI.
1.5. Cardiovascular Risk Factors and MCI
The relationship between cardiovascular risk factors and cognitive functioning is
well known as a result of a rich literature base (See Section 1.2.). However, the
literature base associating cardiovascular risk factors with MCI specifically is much
sparser. While MCI may be seen as an obvious corollary of continuous cognitive
function, this important diagnostic entity requires more focused studies in order to
determine the contribution of cardiovascular risk factors to a clinically defined condition
of cognitive impairment. Table 2. summarizes some of the most well-cited studies in this
small but developing literature base. These studies vary in design and follow-up
periods, but all attempted to associate cardiovascular risk factors with MCI specifically,
and not continuous cognitive function. To date, the risk factors studied include
hypertension, coronary artery disease (CAD), stroke, Type II Diabetes, Total
Cholesterol (TC), High Density Lipoprotein (HDL), Low Density Lipoprotein (LDL),
Triglycerides (TRIG), HCY, APOE Genotype, and vascular brain damage in the form of
white matter lesions, infarcts, and atrophy.
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Study
(Solfrizzi et
al., 2004)
(Cheng et al.,
2012)
(J. A.
Luchsinger et
al., 2007)
(Faux et al.,
2011)
(Kim et al.,
2007)

Design
Prospective

Table 2. Review of Cardiovascular Risk Factors for MCI
Risk Factor(s)
Results
Hypertension, CAD, Stroke, Type 2 Diabetes,
CV Risk factors likely increase the risk of MCI progression to
TC, HDL
dementia, but did not find that these factors predict higher MCI risk

MetaAnalysis

Type 2 Diabetes

Higher incidence of MCI in subjects with Diabetes

Prospective

Type 2 Diabetes

Diabetes predicts MCI prospectively

Homocysteine

Hcy did not relate to MCI

Homocysteine

Hyperhomocysteinemia linked to MCI in an older cohort

Prospective

Hypertension, TC, Antihypertensive medication,
Type 2 Diabetes

Midlife SBP and TC predicted MCI, diabetes and antihypertensive
meds did not

(O. L. Lopez
et al., 2003)

Prospective

Hypertension, APOE, Vascular brain damage (MRI),
Stroke, Type 2 Diabetes, Heart Disease

Hypertension, APOE genotype, MRI evidence of white matter
lesions/infarcts, diabetes, and heart disease all predicted MCI
prospectively. Stroke did not predict MCI.

(Rasquin et
al., 2004)

Prospective

Stroke

Stroke predicted MCI at one year follow up but evidence this
impairment may be reversible

(Reitz et al.,
2007)

Prospective

Hypertension, APOE

Hypertension predicted 5 year all cause MCI and non-amnestic MCI,
but not amnestic MCI. No interaction with APOE genotype.

(Reitz et al.,
2008)

Prospective

TC, HDL, LDL, TRIG, Lipid-lowering treatments

No relationship between serum lipid levels and MCI, no effect of
lipid-lowering treatments on MCI risk

(Toro et al.,
2014)

Prospective

TC, APOE

Higher TC predicted MCI over 14 year time period but did
not interact with APOE

(D. et al.,
2010)

Cross
sectional

TC (Familial Hypercholesterolemia), APOE

Familial hypercholesterolemia associated with MCI,
independent of APOE genotype

(M Kivipelto
et al., 2001)

CrossSectional
CrossSectional
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At present, results associating these risk factors with MCI are somewhat mixed.
A few of the major studies demonstrated an association between common
cardiovascular risk factors like hypertension, diabetes, and lipid levels on MCI, but
others reported no association. Some of these inconsistencies are likely due to
differences in MCI diagnosis. The literature base is strong enough to warrant further
study, both in the interest of replication and new hypotheses. There are many gaps in
the cardiovascular risk factor and MCI framework that can be addressed. No studies
associating PWV measured arterial stiffness or GFR measured renal function with MCI
were found. Homocysteine studies have been done and while informative they are
mostly cross-sectional, resulting in an obvious need for a prospective study of HCY and
MCI. Furthermore, while APOE genotype has been studied there is a need for more
testing of interactions between APOE genotype and cardiovascular risk factors. This
gap coincides with an overall lack of studies that associate the aggregation of multiple
cardiovascular risk factors, and how they may interact to contribute to MCI risk. This
study will attempt to address some of the gaps in this literature, as well as replicate
other findings.
1.6. Cardiovascular Risk Factor Scales
1.6.1. Cardiovascular Risk Prediction Models
It is now well known that the combination of multiple cardiovascular risk factors
can aggregate and contribute to CVD risk (Goff et al., 2014; Piepoli et al., 2016; Yusuf
et al., 2004). However, it can be difficult to quantify exact risk for a patient who visits his
or her clinician with a handful of risk factors, some of which may not reach clinically
established “cut-offs” for what constitutes risk. In an effort to make risk calculation
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easier for individual patients, various groups from large epidemiological studies on
cardiovascular health have devised risk models using Cox Regression hazards models
in order to identify variables and their individual contribution to risk. Because these
studies are focused on cardiovascular health, the outcome “event” being predicted by
these models is usually some degree of first time CVD or specifically first time Coronary
Heart Disease (CHD). These models are constantly evolving to incorporate new risk
variables and more data from larger study populations, but there is an emphasis on
keeping the models as simple as possible for use in a clinic setting to quickly quantify a
patient’s 10 year risk of CVD/CHD.
The basic foundation for many of these cardiovascular risk prediction models
comes from early attempts by the Framingham Heart Study to quantify CVD Risk
(Kannel, McGee, & Gordon, 1976). Framingham’s General Cardiovascular Risk score
has since been refined with additional decades worth of data, and has now been
adopted to a simple point scoring system that incorporates age, sex, SBP, hypertensive
medication treatment, TC, HDL, smoking status and diabetes (D’Agostino et al., 2008).
This Framingham Risk Score (FRS) was developed using cox regression to investigate
the 12 year risk of a first CVD event using a sample of 8491 Framingham study
participants. The FRS does very well at predicting various CVD events including CHD,
Stroke, Intermittent Claudication, and Congestive Heart Failure. The score is useful in
clinical settings because it is simple and based on fundamental cardiovascular variables
that would be gathered in relatively routine checks. It has been incorporated into many
simple online calculators for a quick estimate of 12 year first-time CVD risk. See
Appendix A for FRS scoring tables adapted from D’Agostino et al. 2008.
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The FRS is not without critique however, with some research groups pointing to
its lack of certain factors such as ethnicity, and other risk factors as flaws that can be
addressed by a more robust risk prediction model. The SCORE project in Europe
developed as a collaboration between 12 large cohort studies, collectively including
over 200,000 participants, to devise a risk prediction model for Europeans (Conroy et
al., 2003). Like the FRS, SCORE includes age, sex, smoker status, TC, HDL, and SBP,
although age is included not as a risk factor in itself but as a measure of exposure time
to other risk factors. The model also includes nationality as a risk modifier by identifying
certain populations as “high-risk” (Russia, Latvia, Georgia etc.) and others as “low-risk”
(Germany, United Kingdom, Italy etc.). SCORE is somewhat unique in comparison to
other risk models like Framingham in that it specifically predicts fatal cardiovascular
events over a 10 year period, and not cardiovascular events based on a clinical
threshold. Unlike several other risk models, SCORE does not include diabetes due to a
data limitation in that not all of the included cohort studies had diabetes data (Conroy et
al., 2003).
Other models have attempted to include data on risk factors that they felt were
lacking in Framingham’s original risk scores. For example, the ASSIGN score from the
Scottish Heart Health Extended Cohort includes family history and social deprivation in
addition to the traditional FRS risk factors (Woodward, Brindle, & Tunstall-Pedoe, 2007).
The PROCAM scoring scheme for coronary event risk incorporates family history and
additional serum lipid levels including LDL and TRIG (Assmann, Cullen, & Schulte,
2002). The Reynolds Risk Score for women was developed to specifically address the
large number of coronary events that were occurring in women who did not have the
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risk factors included in the older Framingham risk models (Buring & Cook, 2007; Khot et
al., 2003). In their model, based entirely on coronary event risk in women, they included
additional apolipoproteins, C-Reactive Protein (CRP), and parental history, among other
factors. In addition to these risk factors, diabetes was conceptualized not
dichotomously, but as a continuous variable reflecting hemoglobin A1C levels. While the
inclusion of additional risk factors may seem to create a more inclusive model, they
complicate the original conception behind cardiovascular risk prediction models in that
they should be simple and easily applicable in an office setting. Furthermore, there is
some evidence that the simpler models like FRS and SCORE still outperform more
complex models like PROCAM in terms of determining absolute CVD risk over the time
periods they specify (Versteylen, Joosen, Shaw, Narula, & Hofstra, 2011).
One of the most recent attempts to formulate a CVD risk prediction model that
includes Framingham’s base risk factors but addresses ethnicity concerns comes from
a 2014 report from the American College of Cardiology/American Heart Association
(Goff et al., 2014). This risk model specifically predicts the risk of an arteriosclerotic
cardiovascular event, including heart attack and stroke, and is abbreviated ASCVD risk
(arteriosclerotic cardiovascular disease). In an attempt to address a flaw in the FRS,
primarily that it was based on a predominantly white New-England sample, the ASCVD
risk score includes a separate risk algorithm for black patients in addition to separate
algorithms for men/women and hypertensive treatment/no-treatment. Besides these
additions, the score is still derived from age, TC, HDL, SBP, smoker status, and
diabetes just like the FRS in an attempt to keep the score based on routinely collected
data. Other risk factors including DBP, family history, GFR, and BMI were investigated,
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but they did not significantly improve model discrimination for 10-year ASCVD. Unlike
the FRS, the ASCVD score has not been adapted to a simple point scoring system but
is still based on an easily implemented algorithm and can similarly be quickly provided
by various online calculators. See Appendix B for risk scoring algorithms adapted from
Goff et al. 2013.
It is evident that there is a growing number of CVD risk prediction models
presently in circulation, and this can create a problem for physicians trying to determine
which model to use in their own patients. A recent review expanded on this issue,
claiming that the number of risk models currently in use is excessive, and more efforts
should be made to externally validate existing models using large epidemiological
datasets rather than create new prediction models (Damen et al., 2016). Aside from the
FRS and SCORE, very few of the models in circulation have undergone rigorous
external validation (Damen et al., 2016). Some have suggested that risk prediction
models are most appropriately used for individuals who resemble the study sample from
which the model was derived (e.g. FRS for white New-England residents; Wilson et al
1998). Regardless of the issues of oversaturation of risk models and demographic
concerns, these models are still extremely useful for predicting CVD events in patients
who may have multiple marginal risk factors that may not warrant individual treatment
(D’Agostino et al., 2008; Grundy et al., 1999; Wilson et al.,1998).
1.6.2. Using Cardiovascular Risk Prediction Models beyond CVD
Section 1.2. established that there is an extensive literature base associating
cardiovascular risk factors with cognitive function, and Section 1.5. discussed growing
evidence that cardiovascular risk factors may predict MCI risk. It is possible that an
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aggregation of cardiovascular risk factors may interact to increase MCI and cognitive
decline risk in a similar manner to predicting CVD incidence. Current risk models are
based on specific CVD outcome events like CHD, but they may have some use in
predicting other conditions like MCI given what is now known about cardiovascular risk
factors and their ability to predict other conditions outside coronary events alone,
including dementia (Miia Kivipelto, Ngandu, & Fratiglioni, 2005; J. Luchsinger et al.,
2005; Whitmer, Sidney, Selby, Claiborne Johnston, & Yaffe, 2005). Despite the models
being tailored for another condition, they are still based on fundamental cardiovascular
risk factors, and may elucidate the role of these variables in MCI risk. Similar
approaches have been used to assess the relationship between cardiovascular risk
profiles and cognitive function, with Framingham’s stroke risk profile shown to predict
not only stroke risk, but cognitive decline in general (Elias et al., 2004). In some cases it
has been reported that cardiovascular risk profiles have bested even specifically
developed dementia risk scores in the prediction of future cognitive impairment
(Kaffashian et al., 2013).
1.7. Objectives and Hypotheses
1.7.1. Primary Objectives
The primary objectives of this study will be to address the current gaps in the
cardiovascular risk factor and MCI literature using the large community-based sample of
the Maine Syracuse Longitudinal Study (MSLS). Hypotheses are based on previous
studies from the MSLS associating cardiovascular risk factors with cognitive
impairment, as well as the literature reviewed in Section 1.5. speculating an association
between cardiovascular risk factors with MCI and Dementia. All hypotheses are
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expected to hold under adjustment for basic model covariates including age, sex, years
of education, and ethnicity. Primary objectives are as follows:
1. Determine whether cardiovascular risk factors including SBP, GFR, THCY, Serum
Lipids (TC, HDL, LDL, TRIG) and Diabetes predict MCI prospectively. Additionally,
determine whether arterial stiffness associates with MCI cross-sectionally.
Hypothesis: We predict that higher SBP, THCY, and TRIG will be associated with
higher MCI risk and that higher MCI risk will be seen is diabetics. We also predict
that HDL and GFR will be associated with lower prospective MCI risk. No
relationship between TC and LDL with MCI risk is expected. Finally, we predict
higher PWV among those categorized as MCI compared to CN.
2. Determine whether APOE genotype moderates the relationship between the
cardiovascular risk factors included in this study and MCI.
Hypothesis: We predict that APOE genotype will moderate the relationships
predicted in Objective 1 such that the presence of an APOE ε4 will exacerbate
the direct relationship between SBP, THCY, TRIG, and PWV with MCI, and
attenuate the inverse relationship between HDL and GFR with MCI.
3. Determine whether an aggregation of cardiovascular risk factors categorized
dichotomously into disease/non disease states (hypertension, CKD, diabetes etc.)
predicts greater MCI risk prospectively. This aggregation is represented in the MSLS
Cardiovascular Risk Factor Scale (MSLS-CVRFS; See Section 2.5.1. in the Methods).
Hypothesis: We predict that a higher score on the MSLS-CVRFS will
prospectively predict greater MCI risk.
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4. Determine whether existing cardiovascular risk models designed to predict CVD over
a 10-12 year period also predict MCI risk. The two models tested in this study will be the
FRS (D’agostino 2008; See Section 2.5.2) and the ASCVD Risk Score (Goff 2013; See
Section 2.5.3.)
Hypothesis: We predict that both the FRS and ASCVD Risk score will
prospectively predict greater MCI risk.
1.7.2. Secondary Objectives
Secondary objectives of this study involve supplementary analyses related to the
findings of the above primary objectives.
1. Compare the three cardiovascular risk scales used in this study (CVRFS, FRS, and
ASCVD Risk Score) in their ability to predict MCI.
Hypothesis: While we expect that all three scales will predict higher MCI risk, we
predict that the FRS and ASCVD Risk Scores will perform similarly and both
outperform the CVRFS. The rationale for this hypothesis is based on the fact that
the FRS and ASCVD Risk Score include critical demographic information
including age, sex, education whereas the CVRFS is based composed only of
cardiovascular variables.
2. Determine whether the CVRFS prospectively predicts cognitive performance
measured on a continuum, as opposed to a dichotomous MCI diagnosis. The cognitive
composites included in this analysis are outlined in Section 2.3., and are the same
measures that determined MSLS MCI diagnosis (See Section 2.6.).
Hypothesis: We expect the CVRFS to prospectively predict each of the cognitive
composite scores (Verbal Memory, Visuospatial Organization and Memory,
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Scanning and Tracking, Working Memory, Executive Function, and Global
Function) in linear regression models including age, sex, education, and
ethnicity.

33

2. METHODS
2.1. The Maine Syracuse Longitudinal Study Design
The Maine Syracuse Longitudinal Study (MSLS) was started in 1974, and has
assessed the relationship of cardiovascular health to cognitive functioning over several
decades. Initially, the study was primarily interested in idiopathic and uncomplicated
hypertension but has since expanded to include various cardiovascular risk factors
including arterial stiffness, diabetes, plasma homocysteine, cholesterol levels, kidney
function, cardiovascular diseases, and nutritional determinants of cognitive
performance, including vitamins. The MSLS includes seven waves of examination with
seven cohorts of participants defined by time of entry into the study. A total of 2464
participants have participated in at least one examination (See Table 3.). The first four
waves of the study were conducted at SUNY Heath Science Center Upstate New York
via collaboration between Merrill F. Elias, Principal Investigator, and David H. P.
Streeten, investigator and Professor of Medicine. In 1996 the Maine Syracuse
Longitudinal Study acquired its own laboratory space in Syracuse, New York but
Table 3. Design of the MSLS
W1
C1

E1

C2

W2
→

W3

W4

W5

→

E3

→

E4

→

E5

→

E6

→

E7

E1

→

E2

→

E3

→

E4

→

E5

→

E6

E1

→

E2

→

E3

→

E4

→

E5

E1

→

E2

→

E3

→

E4

E1

→

E2

→

E3

E1

→

E2

C4
C5
C6
234

W7

E2

C3

C7
N

W6

494

679

W= Wave

717
C=Cohort
34

1506
E=Exam

1176

E1
841

continued to collaborate with medical staff at SUNY Health Sciences Center. Figure 4.
displays the different locations involved in the MSLS study including where specific
assays were done.

Syracuse Lab
Cognition/Medical

Oxford, UK
Homocysteine

Centrex Syracuse
Panel + Vitamin B12

Cambridge, UK
Vitamin B6 + C-Reactive Protein

Maine
Data/Admin

Birmingham, UK
ApoE

Figure 4. MSLS Structure and Assessment Locations

The MSLS has a long history of relating cardiovascular risk factors to cognitive
functioning along a continuum, setting the framework for using similar risk factors to
predict a dichotomous variable like MCI. A recent review of the literature summarizes
these studies in the context of the history of the study of cognitive performance and
hypertension (M.F. Elias et al., 2012). The MSLS was the first longitudinal study
designed to examine relations between hypertension and cognition over the lifespan,
following a small initial study by Wilkie and Eisdorfer (Wilkie & Eisdorfer, 1971). Here we
summarize data from particularly illustrative studies.
The MSLS has previously shown a negative relationship between high blood
pressure and cognitive function (Crichton, Elias, Davey, & Alkerwi, 2014; M F Elias,
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Robbins, Elias, & Streeten, 1998; P. K. Elias, Elias, Robbins, & Budge, 2004), as well
as blood pressure variability across measurements and cognitive function (Crichton,
Elias, Dore, Torres, & Robbins, 2014). The study has furthermore evidenced
relationships between lipid profiles and cognitive function (Crichton, Elias, Davey,
Sullivan, & Robbins, 2014), arterial stiffness as measured by PWV and cognitive
function (M.F. Elias et al., 2009; M F Elias, Crichton, & Abhayaratna, 2015), as well as
an interactive effect of the APOE ε4 allele and diabetes on cognitive functioning (G. A.
Dore et al., 2009). An interaction between APOE genotype and homocysteine has also
been reported (M F Elias et al., 2008). Many of these studies are prospective in design,
using risk factors to predict cognitive function after a period of several years. The
current study uses a similar methodology to these past projects, which support our
preliminary hypotheses in their findings.
2.2. Procedure
Paper and pencil questionnaires including general medical information,
demographic data, job stress questions, sleep disturbance, Cornell Medical Index, and
health habits (vitamins, supplements, smoking, alcohol consumption etc.) are completed
at home. Participants then came into the lab around 9 AM following a fasting period
from midnight (unless diabetic). Participants in the study provided medical interview
information on physical health, mental health, and demographics prior to
neuropsychological testing. Blood samples were taken first when the participant arrived,
followed by fifteen blood pressure measurements (five each recumbent, sitting, and
standing) and pulse wave analysis (PWV). Following a light breakfast, a physical
examination with medical history review and review of current treatments and
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medications was done. The participant then participated in the MSLS
Neuropsychological Battery consisting of over twenty tests and subscales including the
Wechsler Memory Scale-Revised (WMS-R), the Wechsler Adult Intelligence Scale-III
(WAIS-III), Mini Mental State Exam (MMSE), and Boston Naming Test among several
other assessments. Assessment order was identical across all participants. Cognitive
testing was done at each of the seven waves of the studies with small variations in test
types due to scale revisions, and measurement of additional cognitive domains.
Following the examination a summary of each subject’s medical and cognitive
examination was sent to them with a request that they (the study participants) contact
their family physician or other specialist and go over the report with them.
2.3. The MSLS Cognitive Test Battery
Cognitive performance was first assessed via the original Wechsler Intelligence
Scale and the Halstead-Reitan Neuropsychological Test Battery. In 1993 the
Framingham Test Battery was added as a special subset of tests. Eventually specific
tests were chosen to be given at each wave and defined as the Maine Syracuse
Longitudinal Test Battery. The test battery used continuously distributed cognitive tests,
however many clinical tests were available for use in diagnosis of clinical impairment.
The “MSLS Battery” (core battery) tests used to derive composite scores (factors
or domains) and the names of the composite scores are outlined in Appendix C. The
scores used were all continuously distributed and were largely taken from the Wechsler
Intelligence Scale and the Wechsler Memory Scales. These composite scores include
Visual Spatial Memory and Organization, Verbal Memory, Working Memory, Scanning
and Tracking (See Appendix C for a list of composite scores and tests factored into
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each composite). WAIS Similarities loaded about equally across factors and thus was
used as an independent single test of abstract reasoning. Later an executive functioning
composite was added including Trail Making and Controlled Oral Word Associations.
These composite scores are represented in Z scores with a mean of 0 and SD of 1,
reflecting performance relative to the entire community-based sample. The core battery
also included administration of the MMSE, which is sensitive to cognitive decline over
repeated assessments.
2.4. Cardiovascular Risk Factors
2.4.1. Blood Pressure
Blood pressure (mmHg) was measured in the MSLS using a pressure cuff with a
Critikon Dinamap ProCare 100. Five measures each were taken in standing, sitting, and
reclining position, with a five minute interval in between each measurement. For these
analyses, an average of all 15 measurements was used for systolic blood pressure
(SBP). The average BP across all 15 measurements was also used as a cut off score
for hypertension. Pulse Pressure (PP) was calculated by taking the difference in
average SBP and DBP (see Crichton et al. 2014).
2.4.2. Arterial Stiffness
As part of a new grant and a new direction at Wave 7 of the MSLS, arterial
stiffness was assessed non-invasively using PWV analysis. Using the SphygmoCor
system (AtCor Medical), PWV was measured in supine position with applanation
tonometry. Carotid-femoral path length was defined as the difference between the
surface distances of the suprasternal notch, the umbilicus, and the femoral pulse, as
well as the suprasternal notch and the carotid pulse. Transit time was estimated in 8 to
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10 sequential Electrocardiogram-gated femoral and carotid waveforms as the average
difference between the start of the femoral and carotid waves. PWV was calculated as
the carotid-femoral path length (meters) divided by the carotid-femoral transit time
(seconds).
2.4.3. Homocysteine
Plasma Hcy levels were measured using a fluorescence polarization
immunoassay on an Abbot IMx auto-analyzer at the University of Oxford. Blood
samples were drawn following a period of fasting from midnight. The coefficient of
variation for the tHcy assays was less than 3.5% (M F Elias et al., 2006).
2.4.4. Serum Lipids
Serum lipids including TC, HDL, LDL, and TRIG were obtained from fasting blood
samples using standard assay methods at Centrex Clinical Laboratories. Lipid levels
are presented in milligrams per deciliter blood. Details of blood draws and assays can
be seen in Elias et al. (2006).
2.4.5. Diabetes
Type 2 Diabetes in the MSLS was defined objectively by treatment with insulin or
glucose lowering medications, or by a fasting glucose greater than 126 mg/dL
determined by serum analysis by Centrex Clinical Laboratories.
2.4.6. Renal Function
Kidney function in the MSLS is measured by GFR using the CKD-EPI formula
comprising age, sex, ethnicity, and serum creatinine. Fasting blood samples were
collected in serum separator tubes and sent to Centrex Clinical Laboratories in
Syracuse, NY for determination of serum creatinine. Serum creatinine was determined
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using a two-point rare test type on a Johnson and Johnson Vitros Intrument. Coefficient
of variation was less than 5%.
2.4.7. APOE
APOE genotyping was in the laboratory of David A. Smith, Chairman of the
Department of Pharmacology, University of Oxford, UK, using state of the art methods
of polymerase chain reaction and restriction enzyme digest with HhaI (Hixson & Vernier,
1990). Genotyping was done with interest in determining the presence of the E4 allele,
a risk factor for several brain pathologies and cognitive impairment in late life.
2.5. Cardiovascular Risk Scores
2.5.1. The MSLS Cardiovascular Risk Factor Scale
The MSLS Cardiovascular Risk Factor Scale (MSLS-CVRFS) is a count of
dichotomized cardiovascular conditions and biometrics intended to represent a
participant’s cardiovascular health in terms of clinically defined risk factors. Unlike the
other risk scores presented in this study, the scale is not intended to predict risk for
future CVD but is rather intended to represent a current assessment of a participant’s
cardiovascular condition. The current version of the scale represents 12 risk factors that
either reflect binary disease states (hypertension, diabetes etc.) or have been
dichotomized based on clinically recommended cutoffs (lipid levels, kidney function
etc.). The risk factors included in the scale are as follows: hypertension (≥140 SBP
and/or ≥90 DBP), diabetes, cardiovascular disease (history of 1 or more of angina
pectoris, coronary artery disease, myocardial infarction, heart failure, and transient
ischemic attack), Obesity (≥30 BMI), Apoe ε4 (presence of 1 or 2 ε4 alleles), smoking
(current smoker), Low HDL (<40 mg/dL), High LDL (>160 mg/dL), High TRIG (>200
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mg/dL), High THCY (>13 μmol/L), High CRP (>3 mg/L), Low EPI GFR (<60 mL/min).
These risk factors were then aggregated to form the CVRFS, which ranges in score
from 0 (no risk factors) to 12 (all 12 risk factors included in the scale).
Five hundred and ninety participants in the sample had complete data for all 12
cardiovascular risk factors (35 participants were excluded for missing data) and a
CVRFS score was calculated for each. Figure 5. displays the frequency of each score
on the cardiovascular scale (e.g. 56 individuals in the sample had no cardiovascular risk
factors). The mean CVRFS score was 2.67 (SD=1.75) with a median and mode of 3.
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Figure 5. Frequency of CVRFS Score in Study

41

11

12

The CVRFS is slightly skewed due to a small number of individuals (n=5) having
scores beyond CVRFS=7 (see Figure 5.). To adjust the scale and meet assumptions for
normality required for a linear regression, the scale was truncated to include these five
individuals in a new CVRFS=7+ category (see Figure 6.). This new distribution is
relatively normal and was used to conduct the linear regressions. With truncation the
CVRFS had a mean of 2.65 (SD=1.70), a median of 3, and a mode of 3. Although
normality is not a requirement for logistic regression the truncated version of the CVRFS
was used in all analyses for consistency.
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Figure 6. Frequency of Truncated CVRFS Score
Table 4. displays the frequency of each risk factor at various levels of the
CVRFS. Hypertension was the most common risk factor at each level of the scale,
representing 32% of the participants who had just one risk factor, and was present in
95% of the participants who scored ≥ 5 on the CVRFS. Proportion of each risk factor
increased with increasing CVRFS score, and while certain risk factors were more
common (hypertension, obesity etc.) we feel each risk factor included in the scale is
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adequately represented. Basic demographic info is also displayed. On average, the
groups that scored higher on the CVRFS appeared to be slightly older, less educated,
and had a higher proportion of males and non-white individuals.
Table 4. Proportion of Sample with each Risk Factor in the CVRFS by Number of Risk Factors +
Demographics
CVRF=0
CVRF=1
CVRF=2
CVRF=3
CVRF=4
CVRF=5+
Risk Factor
N= 56
N=106
N=129
N=130
N= 86
N=83
Hypertension
Diabetes
Cardiovascular
Disease
Obesity
Apoe ε4
Current Smoker
Low HDL
High TRIG
High LDL
High THCY
High CRP
Low GFR
Demographics
Age (years)
Sex (% female)
Education (years)
Ethnicity (%
white)

0
0

.32
.01

.56
.03

.74
.09

.81
.16

.95
.43

0

0.00

.05

.15

.17

.39

0
0
0
0
0
0
0
0
0

.05
.24
.03
.01
.02
.10
.02
.17
.04

.33
.25
.07
.05
.04
.12
.05
.35
.10

.58
.30
.08
.12
.10
.15
.09
.50
.10

.63
.41
.12
.22
.24
.21
.13
.67
.22

.76
.41
.22
.48
.51
.14
.33
.72
.41

58.93
(11.3)
71%
15.8
(2.34)

61.34
(13.15)
66%
14.95
(2.82)

63.07
(13.09)
60%
14.50
(2.883)

61.48
(10.65)
62%
14.93
(2.57)

64.78
(10.72)
58%
14.41
(2.42)

62.71
(11.12)
49%
13.33
(2.61)

100%

94%

96%

95%

93%

80%

Standard deviation presented in parentheses where applicable

2.5.2. The Framingham Risk Score
The FRS is described in detail in Section 1.6.1. The score was calculated at
baseline for MSLS participants consistent with the scoring tables presented in
D’Agostino et al 2008 and Appendix A. The FRS is based off an individual’s sex, age,
HDL, TC, SBP, hypertensive treatment, smoker status, and diabetic status. A higher
FRS score indicates a higher CVD risk over 12 years follow-up. The FRS was only
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utilized in this study for participants with complete data for the variables included in the
algorithm (n=615). The sample had a mean FRS of 12.87 (SD=5.54) with risk scores
ranging from -3 to 25. The FRS can also be converted to a risk percentage for CVD
using conversion tables presented in D’Agostino et al 2008, though this approach was
not used for this study.
2.5.3. The Arteriosclerotic Cardiovascular Disease Risk Score
The ASCVD Score is described in detail in section 1.6.1. The score is
represented as a 10-year risk percentage for arteriosclerotic CVD. The ASCVD risk
score was calculated for MSLS participants consistent with the risk algorithms
presented in (Goff et al., 2014) and Appendix B. Like the FRS, the ASCVD includes sex,
age, HDL, TC, SBP, hypertensive treatment, smoker status, and diabetic status. The
scoring algorithm also incorporates ethnicity, with separate coefficients for whites and
African Americans. ASCVD risk score was only calculated for white or African American
participants who had complete data for the variables included in the algorithm (n=607).
The sample had a mean ASCVD risk percentage of 15.29% (SD=16.32%) and scores
ranged from 0% to 85%.
2.6. Defining MCI in the MSLS
The proposed study uses data from the final two waves of the MSLS (wave 6 and
7) for two reasons: 1). These waves offer the most complete and comprehensive set of
data in terms of cardiovascular and cognitive variables; and 2). these waves have the
highest average age in the study (Wave 6 M=62.43, SD=12.85; Wave 7 M=65.28,
SD=12.72).This age range targets the potential at-risk population for MCI. Given the
importance of previous functioning to the diagnosis of MCI, it is necessary to assess
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decline in function over time (from Wave 6 to 7). 762 study participants were assessed
at both examinations. Of these participants, 625 had complete cognitive battery data for
both waves. These examinations were an average of 5 years apart (M=4.64, SD=.72),
allowing a decline in function from a previous baseline. Therefore, MCI diagnosis is
made at Wave 7 if the criterion for decline is met.
The MSLS has not included a formal diagnosis of possible MCI prior to the
proposed work, albeit dementia has been defined. The MSLS categorization for
possible MCI is based on common MCI criteria outlined in Section 1.4.2. The individual
must be free from dementia, have maintained independence in daily function, and show
a decline in cognitive function from previous level. Thus for both waves 6 and 7,
exclusions from the sample were for dementia (as defined by the MSLS dementia
committee and current criteria). Subjects with diagnosed alcoholism and psychotic
mental illness or institutionalization, or who could not speak English were excluded from
the study the study at its inception. There was no restriction on age at entry into the
study. However, it has always been the policy that individual investigators may use their
own set of exclusions as dictated by study goals. Such is the case for the proposed
work.
The criteria used for diagnosis of MCI are sensitive to single-domain or multidomain MCI in that the individual would be marked as possible MCI with a large
decrease in performance in one domain, or with smaller decreases in performance
across multiple domains. Initially, we used the commonly employed criterion of a drop in
performance of 1 SD, and considered this a sign of possible MCI. A drop of .5 SD in
multiple domains (or Global Function) was considered possible MCI to include multi-
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domain phenotypes in order to identify persons who show a drop in performance in
multiple cognitive domains. These domains are outlined in Appendix C. However,
because archival diagnosis of MCI can be difficult, we decided to increase the
requirements for possible diagnosis to a 1.5 SD drop in a single domain or multiple 1
SD drops across several domains (or Global Function). These stricter criteria were used
in an effort to limit false positive diagnoses. Additionally, a drop in MMSE score of 4 or
more was considered an additional marker of possible MCI, as this is a large drop over
5 years. This criterion alone does not suffice as an indicator of MCI because persons
can drop 3 points or more and return to normal functioning on the MMSE at a third
measurement point. Figures 7-9. display the pattern of cognitive changes from baseline
to follow-up between participants categorized as MCI vs CN (Non-MCI).
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Figure 7. Baseline Cognitive Composite + MMSE Standardized Scores
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Figure 9. Average drop in performance on Cognitive Composites and
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2.7. Sample Characteristics
Following exclusions for probable dementia (n=6), a total sample of 625
individuals was examined at both Waves 6 and 7 of the MSLS and had complete
cognitive battery data to inform MCI diagnosis. 96 (15.4%) participants met the criteria
for probable MCI outlined in Section 2.6. This proportion is consistent with other large
community based studies and MCI prevalence meta-analyses (Ganguli et al., 2010; R.
Petersen et al., 2010). Subsequently, 529 participants were considered free from
dementia or MCI and were categorized as Non-MCI or CN. Average baseline age for
the non-MCI sample was 60.70 (SD=11.50), whereas average age for the MCI sample
was 69.01 (SD=11.51). Activities of daily living were not compromised in either sample,
consistent with common MCI diagnostic criteria. The sample was largely community
dwelling individuals who should be representative of the normal population for these
age ranges. A preliminary look at the demographic data suggests some difference in
cardiovascular risk factors between the two groups, with the MCI sample showing
slightly higher BP, PWV, THCY, and higher incidence of diabetes and stroke (See Table
5. on the following page).
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Variable
Age (years)
Sex (% Female)
Education (years)
Ethnicity (% white)
MMSE (Total Score)
Global Composite (Z-Score)
Diabetes (% Diabetic)
CVD (% Have/had CVD)
BMI
SBP (mmHg)
PWV (m/s)
THCY (μmol/L )
TC (mg/dL)
HDL (mg/dL)
LDL (mg/dL)
TRIG (mg/dL)
GFR (mL/min
APOE (% have at least 1 ε4)
Smoking (% current smoker)
Hypertensive Meds (%
Treated)
CVRFS
FRS
ASCVD Risk Score (%)

Table 5. Demographics Table
Baseline (Wave 6)
Non-MCI
MCI
(n=529)
(n=96)

Follow-up (Wave 7)
Non-MCI
MCI
(n=529)
(n=96)

60.70 (11.50)

69.01 (11.51)

65.39 (11.46)

73.61 (11.55)

63%

49%

63%

49%

14.63 (2.70)

14.49 (2.87)

14.70 (2.72)

14.36 (2.86)

92%

96%

92%

96%

28.33 (1.87)

28.34 (1.91)

28.09 (1.95)

25.80 (2.86)

.19 (.90)

-.33 (.93)

.20 (.92)

-.86 (1.00)

10%

18%

15%

22%

11%

20%

16%

31%

29.63 (6.19)

28.90 (4.69)

29.98 (6.88)

28.28 (4.84)

129.52 (21.47)

134.91 (23.07)

129.89 (19.91)

136.00 (23.16)

n/a

n/a

10.47 (2.95)

11.78 (3.61)

9.56 (3.23)

10.42 (3.09)

10.40 (3.69)

11.74 (3.97)

203.75 (40.12)

196.25 (39.69)

188.56 (39.42)

174.15 (40.51)

54.79 (15.87)

51.01 (13.84)

53.02 (49.25)

49.25 (13.82)

121.98 (33.65)

116.54 (34.36)

112.59 (32.41)

101.04 (34.96)

139.47 (109.04)

147.47 (100.59)

116.64 (77.96)

118.82 (59.91)

79.02 (16.24)

69.46 (17.96)

66.31 (15.74)

58.21 (16.23)

28%

30%

28%

30%

11%

3%

n/a

n/a

47%

57%

57%

70%

2.57 (1.69)

3.09 (1.68)

n/a

n/a

12.44 (5.57)

15.24 (4.75)

n/a

n/a

13.35% (14.35%)

25.75% (21.59%)

n/a

n/a

2.8. Statistical Analysis Strategy
2.8.1. Logistic Regression
Given the nature of our continuous predictor variables (cardiovascular risk factors
such as BP, PWV, and tHcy) and a dichotomous outcome variable (MCI; yes/no), we
will be employing a logistic regression model (Hosmer & Lemeshow, 1989). Unlike
traditional linear regression, which has been often been used in previous MSLS
studies to assess the relationship between continuous predictor variables and cognitive
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performance along a similar continuous scale, logistic regression provides probabilities
of a binary outcome dependent on the predictor variables included in the model. These
odds ratios fit the medical model of binary diagnosis and can be used to predict MCI risk
based on the levels of several cardiovascular variables and covariates. Assumptions
are largely in common with linear regression with regards to absence of multicollinearity
or outliers with undue leverage on the regression equation. However, logistic regression
does not require normally distributed predictor variables (Hosmer & Lemeshow, 1989).
Because change in probability is not linear, the logistic regression maps observed data
onto a logistic function containing the natural logs of each possible odds ratio. This logit
scale is continuous, therefore the log of the odds ratios form a linear function of the
predictor variables. This procedure is useful for assessing relative risk given a model of
cardiovascular variables and covariates, and will indicate whether an aggregation of one
or more risk factors increases the likelihood and individual will be in the MCI group. One
important assumption in logistic regression analysis is that associations between risk
and outcome variables are linear, albeit in the absence of linearity one employs other
scaling methods, e.g. examine quartiles of performance rather than scaling predictors
as continuously distributed. In this study logistic regression will be used to assess the
association of various cardiovascular risk factors and MCI risk. It will not be used as a
classification procedure.
2.8.2. Covariates
Like traditional linear regression, logistic regression also allows for the inclusion
of covariates in the model in a way similar to linear regression analysis except that the
outcome is a yes/no dichotomy. Our selection of covariates is based first on theory and
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clinical relevance, and secondly on empirical examination of relations between
predictors and outcomes. In classical epidemiology there is a requirement that a
variable not be considered a confounder unless it relates to the predictor and outcome.
However, consistent with the behavioral and social sciences we consider theory and
clinical relevance as of the first importance in adding variables.
A significant problem in modeling is that too many covariates will reduce total
variance to the point where there are no results. Consequently, we model in hierarchical
fashion, beginning with zero-order relations, adding a basic demographic mode (age,
sex, education, and ethnicity) and subsequent models until model R2 values indicate no
better prediction of outcomes with added models. We also use backward elimination
procedures, but always lock theoretically relevant variables in the models. Covariate
models in this study will focus on basic demographic info including age, sex, education,
and ethnicity.
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3. RESULTS
3.1. Cardiovascular Risk Factors Predicting MCI
We prospectively predicted MCI with several cardiovascular risk factors and
hypothesized that higher levels of these factors would predict an increased risk of MCI
(with the exception of HDL and GFR, which we expected to be associated with lower
risk). Table 6. displays the results of a series of logistic regression analyses testing
these hypotheses with a zero-order model and a basic covariate model adjusting for
age, sex, education, and ethnicity. The assumptions of logistic regression, including
Hosmer and Lemeshow tests of model fit, were all met unless otherwise mentioned.
Systolic Blood Pressure (SBP; b=.011, p=.026, OR=1.011) and Plasma
Homocysteine (THCY; b=.069, p=.022, OR=1.071) were both positively associated with
MCI as predicted. However neither of these associations remained with adjustment for
the basic model covariates (SBP: b=-.002, p=.748, OR=.998; THCY: b=.018, p=.59,
OR=1.019).
High density lipoprotein (HDL; b=.-.017, p=.03, OR=.983) and Estimated
Glomerular Filtration Rate (GFR; b=-.024, p<.001, OR=.976) were both negatively
associated with MCI consistent with our initial hypotheses. These associations
remained with adjustment for basic model covariates (HDL: b=-.02, p=.022, OR=.980;
GFR: b=-.017, p=.015, OR=.983).
In a cross sectional analysis PWV was significantly associated with MCI (b=.122,
p=.001, OR=1.130). However this association did not remain under adjustment for the
basic model (b=.012, p=.806, OR=1.012).
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Table 6. Logistic Regression Results: Cardiovascular Risk Factors Predicting MCI with Adjustment for Basic
Model Covariates
Zero-Order

Basic Model Adjustment

b

χ²(df)

p

OR

SBP

0.011

4.927 (1)

0.026*

1.011

95% CI
(OR)
1.001:1.021

b

χ²(df)

p

OR

-0.002

.103 (1)

0.748

0.998

95% CI
(OR)
.987:1.01

TC

-0.005

2.828 (1)

0.093

0.995

.990:1.001

-0.003

1.076 (1)

0.3

0.997

.991:1.003

HDL

-0.017

4.689 (1)

0.03*

0.983

.968:.998

-0.02

5.278 (1)

0.022*

0.98

.963:.997

LDL

-0.005

2.053 (1)

0.152

0.995

.988:1.002

-0.003

.848 (1)

0.357

0.997

.989:1.004

TRIG

0.001

0.444 (1)

0.505

1.001

.999:1.002

0.001

2.077 (1)

0.15

1.001

.999:1.003

GFR

-0.024

12.513 (1)

<.001*

0.976

.964:.989

-0.017

5.875 (1)

0.015*

0.983

.969:.997

THCY

0.069

5.277 (1)

0.022*

1.071

1.010:1.136

0.018

.290 (1)

0.59

1.019

.952:1.089

DIABETES

0.618

4.157 (1)

0.041*

1.855

1.024:3.358

0.62

3.622 (1)

0.057

1.859

.982:3.520

PWV^

0.122

10.348 (1)

0.001*

1.13

1.049:1.217

0.012

.06 (1)

0.806

1.012

.923:1.109

* p<.05

^ cross-sectional analysis

3.2. APOE Interaction Terms Predicting MCI
Theoretically relevant cardiovascular risk factors included in the above analyses
and the CVRFS were used to create interaction terms with APOE genotype (ε4 carrier
or not). Out of 614 subjects in the present study with APOE data, 442 have no ε4 alleles
while 172 are ε4 carriers. There was no main effect of APOE in any of the analyses
performed, and in a separate analysis APOE was not significantly associated with MCI
in a simple single factor ANOVA [F(1,612)=.271, p=.603, η2=.000], with 15.2% of nonε4 carriers having MCI compared to 16.9% of ε4 carriers having MCI.
Table 7. displays the results of these APOE interaction analyses as part of a
logistic regression analysis with a model including both variables in the interaction term,
as well as basic model covariates. Of the variables tested, only LDL demonstrated
significant interactions with APOE, however Hosmer and Lemeshow model fit statistics
suggested the LDL X APOE interaction model did not fit the observed data and should
not be interpreted as a significant effect.
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Table 7. Logistic Regression Results: APOE Interaction Terms Predicting MCI with Adjustment for Basic Model
Covariates
Zero-Order

Basic Model Adjustment

b

χ²(df)

p

OR

1.006

95% CI
(OR)
.986:1.028

-0.001

0.005 (1)

0.943

0.999

95% CI
(OR)
.976:1.022

0.579

1.003

.991:1.016

0.003

.165 (1)

0.685

1.003

.990:1.016

0.634 (1)

0.426

0.986

.953:1.020

-0.01

0.319 (1)

0.572

0.99

.957:1.025

3.966 (1)

0.046*

1.015

1.00:1.031

0.014

3.188 (1)

0.074

1.014

.999:1.030

-0.004

2.962 (1)

0.085

0.996

.991:1.001

-0.005

3.553 (1)

0.059

0.995

.989:1.000

APOE*GFR

0.017

1.510 (1)

0.219

1.017

.99:1.046

0.021

2.032 (1)

0.154

1.021

.992:1.051

APOE*THCY

-0.003

.002 (1)

0.962

0.997

.867:1.145

-0.017

0.041 (1)

0.839

0.983

.837:1.155

APOE*DIABETES

0.104

.026 (1)

0.871

1.11

.314:3.923

0.39

.327 (1)

0.567

1.477

.388:5.621

b

χ²(df)

p

OR

APOE*SBP

0.006

.348 (1)

0.555

APOE*TC

0.003

.308 (1)

APOE*HDL

-0.014

APOE*LDL

0.015

APOE*TRIG

* p<.05

3.3. MSLS-CVRFS and MCI
3.3.1. Analysis
A logistic regression analysis was done to predict possible MCI at 5 year follow
up from number of risk factors on the MSLS-CVRFS. Five-hundred and ninety subjects
were included in the analysis, with 94 (15.9%) having possible MCI. The sample had a
mean CVRFS score of 2.65 (SD=1.70) and a range of 0-7. Refer to Section 2.5.1. in the
methods for the full distribution of scores.
3.3.2. Model Fit
A Hosmer and Lemeshow test for model fit determined that the MCI values
predicted by the model did not significantly differ from observed values (χ²=7.441, df=8,
p=.49). Therefore the predicted rates by the model reliably matched the observed rates
of MCI in the sample, and further interpretation of regression analysis was possible.
Figure 10. displays zero-order model predicted MCI relative to observed MCI rates in
the sample.
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Figure 10. Observed and Predicted MCI Proportion based on CVRFS

3.3.3. Relation of MSLS-CVRFS to MCI
The MSLS-CVRFS score at Wave 6 predicted follow up MCI at Wave 7 with
adjustment for the basic model covariates (b=.170, χ²(1)=5.469, p=.019, OR=1.186,
95% CI OR: 1.028-1.368). The MSLS-CVRFS also predicted MCI in a zero-order model
(b=.173, χ²(1)=7.147, p=.008, OR=1.189, 95% CI OR: 1.047-1.349). The odds ratio for
the full model can be interpreted such that for every 1 unit increase in risk (CVRFS
score) the odds associated with MCI increased by 18.6%. However, examination of the
data determined that there are not equal units of risk with increases in the MSLSCVRFS, and therefore a different analysis and interpretation was necessary. As is
commonly done we compared different levels of the MSLS-CVRFS to a CVRFS=0
referent group representing zero risk. Table 8. displays odds ratios evidencing
increased MCI risk for subjects with an increasing risk factor score as compared to a
zero risk factor referent group. However, the apparent reduction in risk moving from

55

CVRFS=2 to CVRFS=3 warranted further exploration to observe the pattern of
increased risk with increased CVRFS score. Table 9. displays the same analysis with
different groupings, with CVRFS=2 and CVRFS=3 being grouped together and CVRFS=
4+ replacing CVRFS=5+. This reconfiguration of risk factor groups reveals that moving
from 1 to 2 or 3 risk factors increased the risk of MCI, but the largest increase in risk
was observed in individuals who exceeded 4 on the CVRFS. These comparisons to a
CVRFS=0 referent group were made with and without control for the basic covariate
model. An additional control for physical activity (metabolic equivalents per week) was
made in a separate analysis but the relation between CVRFS and MCI remained
significant (p<.05 comparing groups CVRFS=2 or 3 and CVRFS=4+ to referent group).
Table 8. Odds Ratios (Zero-order and Basic Model Adjusted) for Each Level of CVRFS Compared to
CVRFS = 0 Referent Group
Zero-Order
Basic Model Covariates
CVRFS

N

Odds Ratio

95 % CI

p

Odds Ratio

95 % CI

p

0 (referent)

56

n/a

n/a

n/a

n/a

n/a

n/a

1

106

4.109

0.899 – 18.772

0.068

3.268

.681 - 15.687

0.139

2

129

6.49

1.481 – 28.4363

0.013*

5.227

1.152 - 23.724

0.032*

3

130

4.062

0.906 – 18.216

0.067

3.363

.733 - 15.440

0.119

4

86

6.652

1.4727 – 30.048

0.014*

4.586

.958 - 21.945

0.057

5+

83

7.172

1.586 – 32.442

0.011*

5.638

1.152 - 27.605

0.033*

* p<.05

Table 9. Odds Ratios (Zero-order and Basic Model Adjusted) for Each Level of CVRFS Compared to
CVRFS = 0 Referent Group (New Grouping)
Zero-Order
Basic Model Covariates
CVRFS

N

Odds Ratio

95 % CI

p

Odds Ratio

95 % CI

p

0 (referent)

56

n/a

n/a

n/a

n/a

n/a

n/a

1

106

4.109

0.899 – 18.772

0.068

3.268

.681 - 15.687

0.139

2,3

259

5.226

1.226 – 22.268

0.025*

4.384

1.007 - 19.083

0.049*

4+

169

7.308

1.700 – 31.425

0.008*

5.067

1.128 - 22.767

0.034*

* p<.05
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3.4. FRS and MCI
3.4.1. Analysis
A logistic regression analysis was done to predict possible MCI at 5 year follow
up from the FRS. Six hundred and fifteen participants were included in the analysis, with
96 (15.6%) having possible MCI. The sample had a mean FRS of 12.87 (SD=5.54) and
ranged from -3 to 25. Figure 11. displays the frequency of FRS in the sample. Because
the FRS algorithm includes age and sex, the basic model covariates included in the
model for this analysis were limited to years of education and ethnicity.
70
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Figure 11. Frequency of FRS

3.4.2. Model Fit
A Hosmer and Lemeshow test for model fit determined that the MCI values
predicted by the model did not significantly differ from observed values (χ²=7.413, df=8,
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p=.49). Therefore the predicted rates by the model reliably matched the observed rates
of MCI in the sample, and further interpretation of regression analysis was possible.
3.4.3. Relation of FRS to MCI
FRS at Wave 6 predicted 5 year follow up MCI (b=.101, χ²(1)=19.599, p<.001,
OR=1.106, 95% CI OR: 1.058-1.157). The odds ratio can be interpreted such that for
every 1 point increase in FRS the odds associated with MCI increased by 10.6%.
3.5. ASCVD Risk Score and MCI
3.5.1. Sample
A logistic regression analysis was done to predict possible MCI at 5 year follow
up from ASCVD risk score. Six hundred and seven participants were included in the
analysis, with 95 (15.7%) having possible MCI. The sample had a mean ASCVD risk
score of 15.29% (SD=16.32%) and a range of 0-85. Recall that ASCVD risk score is
represented as an estimated % of an arteriosclerotic event and therefore can only
possibly range from 0 to 100. The distribution of ASCVD risk score was skewed, but a
normal distribution is not a required assumption of logistic regression. Figure 12.
displays the frequency of ASCVD risk in the sample. Because the ASCVD algorithm
includes the majority of the basic model covariates utilized in this study, including age,
sex, and ethnicity, only years of education was added to the model as a covariate.
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Figure 12. Frequency of ASCVD Risk Scores
3.5.2. Model Fit
A Hosmer and Lemeshow test for model fit determined that the MCI values
predicted by the model did not significantly differ from observed values (χ²=3.701, df=8,
p=.88). Therefore the predicted rates by the model reliably matched the observed rates
of MCI in the sample, and further interpretation of regression analysis was possible.
3.5.3. Relation of ASCVD Risk to MCI
ASCVD Risk score at Wave 6 predicted 5-year follow up MCI (b=.039,
χ²(1)=39.103, p<.001, OR=1.039, 95% CI OR: 1.027-1.052). The odds ratio can be
interpreted such that for every 1% increase in ASCVD risk the odds associated with
MCI increased by 3.9%.
3.6. Comparison of CV Risk Scores in Predicting MCI
3.6.1 Strategy
The sample was limited to only participants who had complete data for the
CVRFS, the FRS, and the ASCVD risk score (N=581). It is important to note that each
scale represents a different unit of measurement. The MSLS-CVRFS represents entire
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risk factors and had a mean of 2.65 (SD=1.70). The FRS is represented in an
algorithmically derived score and had a mean of 12.87 (SD=5.51). The ASCVD risk
score is represented as an algorithmically derived percentage and had a mean of
15.35% (SD=16.49%). While it is possible to represent FRS as a risk percentage like
the ASCVD risk score the scoring algorithm is capped at 30% risk which is a level of
truncation we decided against in order to maintain variance in the distribution of scores.
The ASCVD risk score has not been adapted to a simple point scoring system like the
FRS and therefore it was necessary to use the percentages produced by the algorithm.
While this disparity in units of measurement complicates any interpretation of a
comparison between the three scores in predicting MCI, we still feel it is of value to see
how each score performs at predicting MCI in identical samples. Because of the varying
degrees to which these scales include the demographic variables employed in this
study’s basic covariate model (age, sex, education, ethnicity), these comparisons will be
done as a zero-order logistic regression analysis.
3.6.2. Correlations
The CVRFS, FRS, and ASCVD risk score were all highly positively correlated
with each other as can be seen in Table 10. FRS and ASCVD risk score shared the
strongest correlation at r=.751 (p<.001), while the CVRFS and ASCVD risk shared a
comparatively weaker but still significant positive correlation of r=.271 (p<.001).
Table 10. CV Risk Scores Correlations (n=581)
CVRFS
FRS
ASCVD
CVRFS
1
.501*
.271*
FRS
.501*
1
.751*
ASCVD
.271*
.751*
1
* p<.05
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3.6.3. CV Risk Scores Predicting MCI
All three scores were used in independent zero-order logistic regression
analyses to predict 5-year follow up MCI. Hosmer and Lemeshow tests for model fit
indicated no significant differences between model-predicted MCI and observed MCI
rates for any of the three models, allowing for further interpretation of the regression
coefficients. Table 11. displays the regression coefficients and odds ratios for each of
the three risk scores. The best statistic for comparison of the three models given the
difference in units are the adjusted R2 values, although interpretation of R2 in a logistic
regression should be done with caution (Hosmer & Lemeshow, 1989). Despite this
caution, it is clear that while all three risk scores were significant predictors of MCI at
follow-up, the ASCVD outperformed the CVRFS and the FRS in terms of percent
variance in MCI explained.
Table 11. Comparison of CV Risk Scores Predicting MCI (n=581)
Risk Score
b
χ²(1)
p
OR
95% CI (OR) Nagelkerke R2
CVRFS
0.165 6.502 0.011* 1.18 1.039 : 1.339
0.019
FRS
0.104 20.412 <.001* 1.11 1.061 : 1.161
0.065
ASCVD
0.039 40.018 <.001* 1.039 1.027 : 1.052
0.115
* p<.05

3.7. Cardiovascular Risk Factor Scale and Cognitive Composite Scores
3.7.1. Sample
A series of linear regression analyses was done to predict continuously
distributed cognitive composite scores at 5 year follow up from number of risk factors on
the CVRFS. These analyses employed the same five-hundred and ninety subjects
included in the logistic regression analysis in Section 3.3. Appendix C displays the
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cognitive composites and the factor analyzed cognitive tasks that are included in each
composite score (z-score standardized).
3.7.2. Relation of CVRFS to Cognitive Composite Scores
Table 12. displays the results of the series of linear regressions predicting the
cognitive composite scores from CVRFS score with and without adjustment for the
basic model covariates of age, sex, education, and ethnicity. CVRFS score was
negatively associated with every composite score in a zero-order regression analysis
(p<.001) with a model R2 ranging from 3.5% to 8.6%. The CVRFS was negatively
associated with every composite score in a basic model regression analysis (p<.01) with
the exception of Verbal Memory (p=.089). Model R2 for the basic model regressions
ranged from 25.1% to 51.7%. Figure 13. displays CVRFS plotted against 5-year global
composite follow-up score. A quadratic and cubic trend line fit was tested in addition to
a linear model, and in some cases a cubic trend resulted in an increase in explained
variance of 1-1.5%. Appendix D contains additional plotted trends for the CVRFS and
each of the cognitive composites.
Table 12. Linear Regression Analysis Predicting Wave 7 Cognitive Composite Scores from CVRFS
Score
Zero - Order

Basic Model Adjustment

Outcome

b

p

95%CI (b)

Model
R2

b

p

95%CI (b)

Model
R2

Verbal Memory

-0.112

<.001*

-.160, -.065

0.035

-0.037

0.089

-.079, .006

0.317

Visual Organization
and Memory

-0.133

<.001*

-.179, -.087

0.052

-0.051

.008*

-.089, -.014

0.428

-0.152

<.001*

-.199, -.105

0.064

-0.06

.001*

-.096, -.024

0.504

Scanning and
Tracking
Working Memory

-0.172

<.001*

-.218, -.127

0.086

-0.106

<.001*

-.149, -.063

0.251

Executive Functioning

-0.149

<.001*

-.196, -.101

0.061

-0.068

.001*

-.109, -.027

0.354

Global

-0.171

<.001*

-.217, -.125

0.082

-0.076

<.001*

-.111, -.041

0.517

* p<.05
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Figure 13. CVRFS Score and Global Composite
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4. DISCUSSION
The purpose of this study was to provide new information for the role of
cardiovascular risk factors in the prediction of MCI. Of particular interest was examining
cardiovascular risk factors that are not well represented in MCI studies. In the first
phase of the study, individual risk factors were related to MCI. In the second phase of
the study, a cardiovascular risk scale was constructed and used as a predictor of
incidence (new cases after baseline) of MCI. The scale was based on a combination of
risk factors representing general cardiovascular health (MSLS-CVRFS; see section
2.5.1.). The MSLS-CVRFS was compared to other cardiovascular risk scores used to
predict cardiovascular-related mortality and disease incidence.
It has long been known that cardiovascular risk factors and diseases can have a
negative impact on brain function and structure and thus influence cognitive function at
all ages (Lertiz, McGlinchey, Kellison, Rudolph, & Milberg, 2012; Waldstein & Elias,
2015). There have been many studies examining risk factors and cognitive function
(See Section 1.2.). However there are much fewer studies associating cardiovascular
health with MCI specifically, especially using cardiovascular risk scores or an aggregate
score like the MSLS-CVRFS used in the present study. Because MCI is becoming an
epidemiologically and clinically significant disease state in the progression of dementia,
it is critically important for studies to identify modifiable risk factors for this condition.
Several analyses were conducted in this study in an effort to use the MSLS to address
some of the gaps in the MCI literature with regard to specific risk factors like GFR and
THCY, as well as cardiovascular risk scores.
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4.1. Overview of Findings
4.1.1. Cardiovascular Risk Factors
Nine cardiovascular risk factors (SBP, TC, HDL, LDL, TRIG, GFR, THCY,
Diabetes, and PWV) were used to predict MCI over a 5-year follow up period of the
present study. Several of these risk factors have not been extensively studied in their
relation to MCI prospectively including GFR, THCY, and PWV. Several others were
included in the study in an effort to add support to previous findings relating
cardiovascular risk factors and MCI: TC, HDL, SBP and diabetes. All of these risk
factors were assessed not only for their individual contribution to MCI risk, but for any
possible interactions with APOE genotype given the importance of genetic influences on
cognitive function. This section discusses results for each risk factor separately in the
context of the study hypotheses and related studies from the literature.
In agreement with original hypotheses, GFR was identified as a positive risk
factor for MCI. Higher GFR, reflecting healthier kidney function, was protective against
MCI. This finding complements the inverse relationship commonly observed between
GFR and continuous cognitive functioning (Elias et al., 2009; Kurella, Chertow, Luan, &
Yaffe, 2004; Kurella, Yaffe, Shlipak, Wenger, & Chertow, 2005; Slinin et al., 2008) but
the results of the present study provide evidence that GFR can predict MCI, a discrete
and important clinical outcome. Although kidney function has been associated with risk
for dementia (Seliger, 2004), and there is some recent cross-sectional evidence that
GFR and MCI are related (Zammit, Katz, Zimmerman, Bitzer, & Lipton, 2015), very few
studies have associated kidney function and GFR with MCI prospectively. Mechanisms
underlying these relations were not examined in the present study, but there is some
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evidence suggesting kidney function can affect arterial compliance (elasticity and
responsivity), and this loss of hemodynamic efficiency can be very damaging to the
small vessels in the brain (See Section 4.3.).
Elevated THCY was identified as a potential risk factor for MCI, although a
statistically significant association was not seen with control for basic demographic
variables, most notably age. This negative association is of interest because THCY has
been associated with dementia and cognitive impairment no dementia (CIND; a
conceptualization of MCI) and this association was moderated by vitamin B12 treatment
such that those with higher vitamin B12 levels had lower risk compared to those with
lower B12 levels (Mary N. Haan et al., 2007). The contribution of THCY to AD risk may
be particularly strong, with results from the Framingham study finding showing a
doubled risk of AD (OR=1.8) in patients for every one standard deviation increase in
THCY (Seshadri et al., 2002). Homocysteine may play a role in brain health by means
of endothelial dysfunction via oxidative stress, increasing the risk of vascular damage.
The damaging effects of hyperhomocysteinemia may contribute to increased risk of MCI
and dementia (including VaD and AD), but to date lowering of THCY with B vitamin
treatments has shown little efficacy in reversing or slowing cognitive decline associated
with these diseases.
Pulse wave velocity studies undertaken in the present research were not funded
by NIH prior to MSLS wave 7 and thus could not be assessed as a prospective predictor
of MCI. However, the current study presents some cross-sectional evidence that arterial
stiffness is related to MCI risk by confining our analyses to Wave 7 where it was
available as a predictor variable. Subjects diagnosed with MCI exhibited higher PWV,
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although this result was not statistically significant with adjustment for age. In another
study with a higher average age than the present study (78.0 compared to 66.7 in our
study at Wave 7), PWV was shown to be elevated in patients with dementia (AD or
VaD) and with MCI compared to CN patients (Hanon et al., 2005). It is important that
arterial stiffness be examined in relation to MCI in larger studies. Arterial stiffening
occurs naturally with age but can also occur as a result of pathological atherosclerotic
processes and it may be a primary mechanism involved in the relation of cardiovascular
health to the brain. Interestingly, PWV has previously been associated with cognitive
impairment even in healthy populations (Pase et al., 2010; Scuteri et al., 2007; Scuteri,
Brancati, Gianni, Assisi, & Volpe, 2005). This may reflect the potential for arterial
stiffness to damage brain areas via a reduction in hemodynamic efficiency (O’Rourke &
Safar, 2005).
We now consider our results for cholesterol. Most notable among the current
study’s results for serum lipids was HDL cholesterol’s role as a potent positive factor
protecting against MCI risk. HDL has been reported previously as a protective factor
with regard to cognitive decline and cardiovascular disease (Crichton, Elias, Davey,
Sullivan, & Robbins, 2014b; Reitz et al., 2008), but evidence for it as a protective factor
against MCI risk is has been sparse prior to the present study. No relationship was
found between TC, LDL, and TRIG with MCI, which supports some previous findings
(Reitz, 2008). As noted earlier, the importance of this finding for MCI in the present
study is that it is a clinically defined outcome that allows yes or no treatment decisions,
an essential requirement in medical diagnosis and disease management (Evans, 1988).
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SBP was shown to be a risk factor for MCI in the current study in zero order
analyses, but not with adjustment for age. The history of hypertension and cognitive
function is well defined, with many studies providing evidence that mid-life hypertension
and higher BP levels are associated with cognitive decline in late life (M.F. Elias et al.,
2012). Past studies with the MSLS data indicate that blood pressure often has to be
combined over multiple waves in order to see associations with cognitive performance
(M.F. Elias, Goodell, & Robbins, 2015; M.F. Elias et al., 2012, 1993). The current study
takes blood pressure from only one wave of examination like the other cardiovascular
risk factors included as predictors. Additionally, the present study has a smaller sample
size and used a discrete MCI outcome in comparison to past blood pressure studies
from the MSLS that associate hypertension with continuously distributed cognitive
function (M.F. Elias et al., 1993). There is also now a fair amount of evidence relating
blood pressure and hypertension to MCI specifically (M Kivipelto et al., 2001; O. L.
Lopez et al., 2003; Reitz et al., 2007). Reitz et al 2007 specifically found that
hypertension predicted all-cause MCI and non-amnestic MCI but not amnestic MCI,
which adds to evidence suggesting amnestic MCI may be more associated with AD
pathology and non-amnestic MCI may be more associated with vascular pathology.
However these distinctions are not conclusive; outcomes for various MCI subtypes are
not so easily predicted (Busse, Hensel, Guhne, Angermeyer, & Riedel-Heller, 2006b)
and dementia pathologies (particularly AD and VaD) are often mixed (See Section
1.3.3.)
Diabetes mellitus was identified as a risk factor for MCI in the present study even
with adjustment for basic demographics, with higher incidence of MCI seen in subjects
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who were diabetic at baseline. This finding is consistent with results reported in several
previous studies as diabetes has previously been reported as a prospective MCI risk
factor (O. L. Lopez et al., 2003; J. A. Luchsinger et al., 2007) and provides supporting
evidence to the claim that there may be a higher incidence of MCI among Type 2
diabetics (Cheng et al., 2012). As is true for hypertension, there is an established
literature base relating diabetes to a decline in cognitive function in late life (Bent,
Rabbit, & Metcalf, 2000; Cukierman, Gerstein, & Williamson, 2005; D. Knopman et al.,
2001; Robbins, Elias, Budge, Brennan, & Elias, 2005). The results of this investigation
add supporting evidence for its role in predicting MCI as a discrete disease outcome.
Importantly, diabetes has been identified as a strong predictor of dementia risk (Alonso
et al., 2009; Lu, Lin, & Kuo, 2009). However not all studies that have explored diabetes
and MCI have reported that diabetes is a prospective risk factor for MCI (M Kivipelto et
al., 2001; Solfrizzi et al., 2004). These differences among studies including our own may
be due to diagnostic criteria used for MCI, which has changed considerably in the last
twenty years, and varying follow-up periods.
The presence of an APOE ε4 allele has been associated with poor
cardiovascular health outcomes and dementia in previous studies (Lahoz et al., 2001;
Saunders et al., 1993). No relations between APOE genotype and MCI, nor any
interactions between APOE genotype and the studied cardiovascular risk factors were
observed. While this finding did not agree with our original hypothesis, findings from the
literature base on APOE and its association with MCI are mixed. Some previous studies
have shown that the presence of an ε4 allele is an independent risk factor for MCI (Guo
et al., 2010; O. L. Lopez et al., 2003). APOE genotype is generally supported as a risk
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factor for cognitive decline and dementia (Alonso et al., 2009; Laurin et al., 2007) by
mechanism of exacerbating inflammation associated with cardiovascular risk factors
(Farrer et al., 1997; Small et al., 2004). Hypertension and cholesterol have been among
the most studied in the interaction of APOE as it pertains to MCI risk, but to date several
studies have not supported this relationship (Zambon et al., 2010; Reitz et al., 2007;
Toro et al., 2014). Larger population based studies are needed to assess the interaction
of APOE genotype and cardiovascular risk factors with respect to MCI risk, as the
literature is already quite clear on dementia risk.
4.1.2 Cardiovascular Risk Factor Scales and Risk Profiles
In agreement with our hypotheses, an aggregation of cardiovascular risk factors
dichotomized into the MSLS-CVRFS predicted MCI at 5-year follow up. A higher MSLS
CVRFS was associated with higher incident MCI. This finding is consistent with both the
commonly used FRS and the recently developed ASCVD Risk Score, which were also
associated with incident MCI. While these established risk profiles (FRS and ASCVD)
have shown great success in predicting risk for CVD, their use in predicting other
conditions related to cardiovascular health is largely unstudied. In the current study we
provide evidence that each of these cardiovascular risk scores can be used to predict
an increased risk of incident MCI.
One important contrast between the MSLS-CVRFS and the FRS/ASCVD risk
scores used for comparison is that the scale developed in this study does not include
any demographic variables such as age and sex. The intent of the MSLS-CVRFS was
to focus on cardiovascular risk factors alone, and therefore, we chose to consider age
as an important demographic covariate rather than as a cardiovascular risk factor. In
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keeping with theoretical conceptions in advancing age in the life-span psychology
literature, our conceptualization of chronological age is as a variable representing an
exposure time in which the prevalence and incidence of CVD is taking place (See
Schroots & Birren, 1990; Settersten & Mayer, 1997). In this life-span perspective,
chronological age should be considered an “empty variable” with no force of its own, but
which encapsulates the combined effect of countless other variables over time.
Although the FRS and the ASCVD performed slightly better in predicting MCI (See
Section 3.6.3.) it is important to note that these scales include age, which is arguably
the single most important risk factor for MCI and clearly the strongest predictor of
dementia. For reference, the baseline age in our study accounted for an estimated 11%
of the variance in follow-up MCI when examined separately. This alone was comparable
to the estimated percent variance explained by the entire FRS and ASCVD scores (See
Section 3.6.3). Notably, the FRS and ASCVD risk score also include sex as a factor,
which has been previously reported as an important risk factor, with MCI occurring more
frequently in men (R. Petersen et al., 2010). These are not criticisms of the risk models
as these scores were developed to predict CVD with as much accuracy as possible,
rather than with the intention of elucidating the exact role of certain risk factor
mechanisms in the development of CVD. In contrast, with the CVRFS we attempted to
model the contribution of cardiovascular risk factors to MCI risk while controlling for the
demographic variables included in the other risk scores. Our results do indeed provide
evidence that cardiovascular risk factors play a role in this risk. When the CVRFS was
modeled with age and sex included as covariates the total model predicted an
estimated 15% of the variance in follow-up MCI, which compares favorably to the
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percent variance accounted for by the other risk scores. Table 13. summarizes model
R2 values for predicting MCI based on how age was handled as a variable.
Table 13. Summary comparing Model R2 predicting MCI from Risk Factor Scales
Age included in
Age included
Scale/Measure
model as
Model R2
in scale
covariate
MSLS-CVRFS
MSLS-CVRFS
FRS
ASCVD
Age alone

No
No
Yes
Yes
N/A

No
Yes
No
No
N/A

2%
15%
7%
12%
11%

These results of the present study have shown promise in the use of
cardiovascular risk profiles to predict MCI, despite the fact that these profiles are
specifically tailored to predict CVD events, with the exception of the MSLS-CVRFS. This
is not the first study from the MSLS to support the value of risk profiles in predicting
cognitive impairment; the Framingham Stroke Risk Score was previously shown to
predict cognitive functioning by Elias and colleagues (2004), albeit the study focused on
individual cognitive outcomes and not MCI. These findings are important considering
the large literature base for the role of the cardiovascular system in brain integrity and
function. Although originally developed to predict CVD outcomes, these results show
that cardiovascular risk scores can also be utilized to predict MCI risk. Our findings have
particular relevance to patient treatment strategies because the information used to
develop these risk scores (BP, cholesterol etc.) is routinely obtained in physician offices
when a metabolic series is performed. It is clear from the present study that a scale
employing an aggregation of risk factors is a better predictor of MCI than individual risk
factors, and this information is easily obtained from physical examination, patient
history, and metabolic profile.
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To our knowledge only one study has developed a risk score specifically tailored
to predicting MCI risk. Researchers from the Mayo Clinic Study of Aging have recently
published a risk scoring system specifically for MCI (Pankratz et al., 2015). The
variables in this scale include both demographic and cardiovascular health variables,
including sex, years of education, hypertension, and diabetes, among others. The
model includes little influence from current age, as it is intended to predict future MCI
incidence based on mid-life cardiovascular health and demographics. As is commonly
done, age was incorporated in the model as a factor of exposure time to risk factors.
Although this risk factor profile shows promise emerging from a study that has been
heavily involved in the development of the construct of MCI, further validation in
different study populations is necessary.
One of the issues in all risk factor scales that employ age is that age is a
powerful predictor of MCI and cognitive performance and can obscure the role of other
risk factors. Scales employed by epidemiologists employ age from an entirely empirical
perspective in order to maximize prediction. Our primary scale (MSLS-CVRFS)
excluded age based on the conceptualization of age as an empty variable in order to
focus on the contribution of cardiovascular risk factors to MCI risk. As discussed above,
regardless of whether one includes or excludes age in a risk factor scale, risk factor
scales combining multiple measures predict MCI better than individual risk factors.
4.2. Summary
In this MSLS sample cardiovascular risk factors predicted MCI in a 5-year
prospective analysis. This included blood pressure, GFR, HDL cholesterol, THCY,
Diabetes and PWV (cross-sectional). Of these associates GFR and HDL were
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particularly strong predictors of MCI risk, with higher levels predicting lower MCI
incidence independent of age, sex, education, and ethnicity. While we expected more
risk factors to predict MCI it was evident that a combination of risk factors as part of a
cardiovascular risk factor scale offered better MCI risk prediction.
The MSLS-CVRFS also predicted MCI risk, and this association was seen with
adjustment for age, sex, education and ethnicity. Moreover, the CVRFS was linearly
associated with the cognitive composite scores that were used in MCI diagnosis. The
FRS for general CVD risk and the recent ASCVD risk score both predicted incident MCI
with adjustment for demographic variables that were not included in the score. These
findings support the role of cardiovascular risk factors in clinically defined cognitive
impairment with older age, and suggest that risk factor scores have more utility than
individual risk factors for predicting risk of MCI
4.3. Mechanisms Underlying Cardiovascular Health and Cognitive Function
The current study did not involve an investigation of potential mechanisms
underlying the association of cardiovascular risk factors with cognitive functioning.
However, it is possible to speculate on these mechanisms based on prior research.
The prevailing theory on how alterations in the cardiovascular system can influence
cognitive function requires a consideration of the subtypes of cerebrovascular diseases
which range considerably in type and severity. Of particular interest is the influence of
the cardiovascular system on major white matter neuronal tracts in the brain. These
tracts are heavily myelinated neurons responsible for rapid processing speed and
communication among different brain regions. Advancements in brain imaging
techniques have allowed for the easy detection of white matter damage or degradation,
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such as White Matter Hyperintensities (WMH). Manifesting as bright white spots on T2
weighted MRI images, WMHs are often clinically silent regions of white matter
degradation possibly due to small vessel diseases. Other microvascular injuries include
lacunar infarcts and cerebral micro-bleeds which are similarly asymptomatic.
White Matter Hyperintensities (also known as Leukoaraiosis) have been related
to cardiovascular risk factors, cognitive function, and dementia. WMH volume has been
associated with the Framingham Stroke Risk Profile as well as several individual
cardiovascular risk factors including hypertension, arterial stiffness, kidney function, and
diabetes (Fornage et al., 2011; Hughes et al., 2013; Jeerakathil et al., 2004; Khatri et
al., 2007; Liao et al., 1997; Longstreth et al., 2005; Skoog, 1998; Van Dijk et al., 2004).
In turn WMHs have also been associated with lowered cognitive performance, with
executive function impairment commonly seen in patients with high WMH burden (Au,
Massaro, Wolf, Young, & Beiser, 2006; Breteler et al., 1994; Carmichael et al., 2010; de
Groot et al., 2001; Longstreth et al., 2005). Larger WMH burden is also seen in AD
cases, with MCI participants showing WMH levels between those observed in AD and
CN participants (Yoshita et al., 2006). It is important to note that white matter volume
changes are considered a normal aspect of aging, with volume gradually increasing
from birth to midlife, after which volume slowly declines (Kennedy & Raz, 2009). Based
on the evidence relating cardiovascular risk factors to WMHs independent of age, it is
reasonable to hypothesize that an increase in cardiovascular risk factors may
accelerate the lifespan curve of white matter volume and potentially influence cognitive
deficits and increased dementia risk.
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The literature suggests a similar association among cardiovascular risk factors
with lacunar infarctions and cognitive impairment. Also known as lacunar strokes, these
cerebrovascular injuries are characterized by small vessel blockages leading to
subsequent cell death in deep brain regions represented by small cavities on brain
scans. Like a major acute stroke, lacunar infarctions are associated with an increase in
cardiovascular risk factors and have been associated with cognitive function and
dementia (Mungas et al., 2005; Vermeer, Longstreth, & Koudstaal, 2007). Findings from
the Nun Study demonstrated a 20-fold increase in dementia incidence in brains with AD
pathology that also had lacunar strokes (Snowdon et al., 1997).
The small cerebral vessels of the cerebrovascular system are susceptible not
only to localized disease but also to damaging inputs from the central cardiovascular
system. These vessels function somewhat differently from other peripheral vessels.
They are constantly in a state of blood perfusion due to lowered vascular resistance as
a result of increased vasodilation (O’Rourke & Safar, 2005). This phenomena is in sharp
contrast to what takes place in peripheral vessels located in the arms for example, that
have much higher vascular resistance and exhibit more vasoconstriction. While the
physiology of these cerebral vessels allows for constant blood perfusion to meet the
large metabolic demands of the brain, it also makes them particularly vulnerable to
damage caused by high pressure waves resulting from a system that has seen a
reduction in arterial compliance. Arterial stiffening resulting in higher PWV and pulse
pressure may be a primary contributor to this damage, even if the reductions in
compliance occur in the central cardiovascular system and not the cerebral vessels
themselves, which are often spared from atherosclerotic processes.
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While there is an abundance of evidence suggesting a mechanistic association
between cardiovascular risk factors and cognitive functioning by way of small vessel
diseases and central hemodynamics, there is an additional issue that needs to be
addressed. If this mechanistic relation is hypothesized, it should stand to reason that
treatment of the cardiovascular risk factors should lower the extent of cerebrovascular
injury and therefore improve or prevent cognitive decline including MCI and Dementia.
The evidence supporting this hypothesis is mixed. Some reviews and studies have
suggested that early treatment of cardiovascular risk factors like hypertension reduces
dementia risk (M.F. Elias et al., 2012; Forette et al., 2002). However, most of these
treatment interventions have been oriented at prevention of cerebrovascular damage
and cognitive impairment to begin with. Importantly, no studies have shown concrete
evidence that these outcomes are completely reversible by treating cardiovascular risk
factors, despite arguments that they are modifiable. Nevertheless the pursuit of viable
treatment interventions for cognitive impairment associated with cardiovascular health is
a critical objective in the study of MCI and dementia and should be a large focus of
future studies.
In summary, while we did not perform studies allowing us to identify
mechanisms in this investigation there is a strong literature base implying the role of
central cardiovascular risk factors in cognitive performance by means of
cerebrovascular damage. The MSLS will be unable to pursue mechanistic investigations
further, but we encourage other studies to consider investigating underlying
mechanisms relating cardiovascular health to MCI.
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4.4. Study Limitations and Strengths
4.4.1. Limitations
While the current study provides important new data on cardiovascular risk
factors in relation to MCI, several limitations should be considered. This study used an
archival diagnosis of MCI that was derived from a full neuropsychological assessment
supported by various medical and social assessments. Here we use the term “archival”
to define a diagnosis that is based on existing data from the MSLS and does not include
further correspondence with the patient. For compliance with privacy protection and
approved MSLS human subjects research protocol we are blind to who the patients are.
Archival diagnosis can be difficult, and care must be taken to apply diagnostic criteria as
rigidly as possible with all relevant data available. Furthermore, archival diagnosis is
limited in comparison to direct contact with the individual as would be the case in a clinic
setting. However, in order to make the diagnosis of MCI as accurate as possible we
strictly adhered to the primary principles of MCI diagnoses outlined in Section 1.4.2.
In accordance with these principles a participant in the MSLS had to exhibit a
decline from previous cognitive function to a sufficient degree, be free from dementia,
and be able to function independently in their everyday life. The MSLS includes data
relevant to all of these principles, and we were therefore able to retrospectively identify
subjects that fit this well-established MCI profile. Furthermore, a stricter definition for
cognitive decline was utilized in the current study in order to limit false positive
diagnoses. This same approach was taken in the Framingham studies of dementia (M F
Elias et al., 2000). Importantly, the MSLS neuropsychological battery is comprehensive
and extensive, and therefore, we were also able to consider all possible cognitive
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decline phenotypes that may represent MCI, including single and multi-domain
impairment.
While seven waves of data have been collected in the MSLS since 1975, the
current study was limited to a 5-year follow-up period because some cardiovascular risk
factors of interest (Serum lipids, THCY, GFR) were not available prior to Wave 6 of the
study (See Section 2.1.). While other MSLS studies, particularly those using blood
pressure and hypertension as primary predictors, have been able to use longer followup periods, we feel the current 5-year period is necessary because we are specifically
investigating a mid to late life sample who carry the highest risk for MCI diagnosis. It
was likewise necessary to maximize the number of cardiovascular risk factors included
in the study, and Wave 6 of the MSLS has the largest number of risk factors available.
The MSLS-CVRFS has some shortcomings related to the fact that we lacked the
sample size to develop a more sophisticated scale based on continuously distributed
cardiovascular risk factors (used in prediction models like the FRS and ASCVD risk
score). Both of these prediction models were based on algorithms derived from large
datasets. In contrast, in the current study we were restricted to two categories (yes/no)
based on current diagnostic standards and counted the number of risk factors to create
our scale. This method essentially weighs each risk factors equally in the scale. This
method allowed us to consider the role of clinically defined cardiovascular risk
conditions to MCI at the cost of some recognition for risk factors that may be just above
or below the clinical cutoff points. The MSLS-CVRFS was developed as a research
instrument and not a formal psychometric scale, with the intent to study the contribution
of a combination of cardiovascular risk factors.
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4.4.2. Strengths
Despite the limitations discussed above, the current study has a number of
important strengths. To our knowledge this study is the first to relate a cardiovascular
risk factor aggregation score to MCI in a prospective design. Additionally, we have
further validated the use of cardiovascular risk factor algorithms, such as the FRS and
ASCVD, in the prediction of negative health outcomes. Furthermore, like the
Framingham risk studies the MSLS sample is a community-based sample with a large
number of older adults, rather than patients recruited from clinics or in-hospital.
While our sample is small relative to large studies like the Framingham Heart
Studies which often include several thousand participants in an analysis, we have one
of the largest test batteries in a NIH funded study with 22 cognitive measures (See
Torres, Elias, Seliger, Davey, & Robbins, 2016).The depth of this cognitive assessment
is not practical in a large sample typical of an observational study. This extensive
cognitive battery is invaluable for investigating decreases in cognitive performance and
formed the basis for our MCI diagnosis. The current study utilized all of the available
data from the cognitive battery. The analyses in this study were strictly restricted to only
individuals who had complete cognitive testing data and attended Wave 6 and 7 of the
MSLS.
4.5. Future Directions
MCI has already been established as a clinically defined precursor to dementia.
Ultimately, its clinical significance is dependent on how well it predicts transition to
dementia because MCI itself is does not interfere with activities of daily living by
definition. MCI has met this condition fairly well, albeit different definitions abound.
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Regardless of various criteria, when a diagnosis of MCI is made reasonably and
empirically based, it predicts much higher transition rates to dementia than are expected
in the general population (Larrieu et al., 2002; Petersen et al., 1999; Petersen, 2011).
Therefore, two transition periods in the assessment of MCI are of critical clinical
importance: The transition from normal functioning to MCI, and the transition from MCI
to dementia.
The current study joins several other studies in providing evidence for the
important role of cardiovascular risk factors in the transition from normal functioning to
MCI. While more studies exploring the role of cardiovascular health in this transition are
needed, the second conversion phase from MCI to dementia also requires investigation.
More work remains to be done exploring risk factors that may exacerbate the second
transition rate from MCI to dementia, with particular attention to cardiovascular risk
factors which may contribute to forms of VaD or mixed vascular-Alzheimer’s pathology
dementia (Merrill F. Elias & Davey, 2009). There are a few studies that have explored
this conversion phase, and have provided evidence that certain cardiovascular risk
factors including APOE ε4 increase the risk for a transition to dementia (Kryscio,
Schmitt, Salazar, Mendiondo, & Markesbery, 2006). More studies are needed,
particularly those investigating possible mechanisms such as arteriosclerosis and
cerebrovascular disease.
Differential diagnosis of MCI should remain a primary goal in epidemiological
studies assessing MCI and dementia risk. These diagnoses can be difficult to make
however as cognitive phenotypes displayed in patients with MCI can be incredibly
heterogeneous (See section 1.4.). However if these different forms of MCI can be
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accurately mapped onto the forms of dementia they specifically predict (e.g. Amnestic
Single Domain MCI -> Alzheimer’s Disease) it will vastly improve the clinical use of an
MCI diagnosis because interventions can be tailored to the specific form of dementia
that the patient is at risk of developing. This is particularly relevant for identifying forms
of cognitive impairment that may predict mixed forms of vascular and Alzheimer’s
pathology as these are underrepresented in a field biased towards AD prediction
(Sullivan & Elias, 2016).
4.6. Conclusion
The current study contributes to identifying risk factors for MCI, which should be
a critical epidemiological goal in the effort to combat increasing dementia rates
worldwide. Dementia is an irreversible condition and efforts to address this disease
should focus on prevention and delaying onset. Of particular value in this effort will be
the identification of modifiable risk factors for which treatment may reduce risk of
abnormal or accelerated cognitive decline with age. Cardiovascular risk factors have
been associated with cognitive decline and dementia (Waldstein & Elias, 2015), and the
current study suggests that they may predict prodromal states of dementia including
MCI. Just as patients are advised to treat cardiovascular risk factors in an effort to
prevent CVD, the risk of dementia associated with an unhealthy cardiovascular profile
should also be considered.
We consider each objective and hypothesis presented in Section 1.7. in turn.
While we did see that individual cardiovascular risk factors could predict MCI incidence,
most of these associations were lost with control for the basic covariate model.
However, this was not the case with GFR and HDL cholesterol, which were associated
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with lower MCI risk. Furthermore, diabetes was associated with an increased MCI
incidence. Contrary to our hypothesis, no moderating effect of APOE ε4 allele was
observed with any risk factor. In agreement with our hypothesis, an aggregation of
cardiovascular risk factors, reflected in our CVRFS, predicted higher risk of MCI. Two
recommended cardiovascular risk factor algorithms, the FRS and ASCVD risk score,
also predicted higher risk of MCI. As originally hypothesized the FRS and ASCVD
performed better in predicting MCI than the CVRFS, likely because the former two risk
scores include age. Lastly, in agreement with our final hypothesis the CVRFS also
predicted continuously distributed cognitive performance measures from the MSLS
cognitive battery.
The present study has many implications for predicting MCI using cardiovascular
risk factors. Among the individual risk factors we studied, GFR, HDL cholesterol, and
diabetes were particularly strong predictors of MCI. However, using a combination of
multiple risk factors may prove more useful in predicting MCI risk than any single risk
factor, even when age is not accounted for. Patients often come to physicians with
multiple cardiovascular risk factors, and these individuals may be more vulnerable to
MCI and conversion to Dementia. We find that our MSLS-CVRFS, the scale developed
in this study, was more successful in predicting individual cognitive outcomes measured
continuously, but the larger importance of this study is in presenting evidence for
predicting MCI as a clinically defined disease that demands a yes/no treatment decision
from physicians. Predicting this risk is especially useful when it can identify MCI so that
interventions can occur long before dementia occurs in an effort to counteract long
prodromal phase of dementia. We strongly recommend that future studies associating
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cardiovascular risk factor aggregation and individual risk factors with MCI should identify
MCI subtypes (amnestic single domain, non-amnestic single domain etc.) in an effort to
develop different risk profiles predicting different types of dementia (AD, VaD, Mixed).
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APPENDIX A: FRAMINGHAM RISK SCORE CALCULATION

Points
-3
-2
-1
0
1
2
3
4
5
6
7
8
9
10
11
12

Age

30-34
35-39
40-44
45-49
50-54
55-59
60-64
65-69
70-74
75+

Table 14. FRS Calculation for Women
SBP (Untreated) SBP(Treated)
TC
HDL Smoker Diabetic
< 120
60+
<120
50-59
120-129
<160
45-49
No
No
130-139
160-199 35-44
140-149
120-129
<35
130-139
200-239
Yes
150-159
240-279
Yes
160+
280+
150-159
160+

Table 15. FRS Calculation for Men
Points Age SBP (Untreated) SBP(Treated)
TC
HDL Smoker Diabetic
-2
<120
60+
-1
50-59
0
30-34
120-129
<120
<160
45-49
No
No
1
130-139
160-199 35-44
2
35-39
140-159
120-129
200-239 <35
3
160+
130-139
240-279
Yes
4
140-159
280+
Yes
5
40-44
160+
6
45-49
7
8
50-54
9
10
55-59
11
60-64
12
65-69
13
14
70-74
15
75+

Tables and scoring adapted from D’Agostino et al. 2008
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APPENDIX B: ARTERIOSCLEROTIC CARDIOVASCULAR DISEASE RISK SCORE
CALCULATION
Method: A coefficient sum C is calculated for a patient with a different algorithm based
on sex, ethnicity (White vs African American Only), and hypertensive treatment status
(Treated vs Untreated). This coefficient sum is then converted to a 10-year risk
percentage in a second equation including parameters based on average values
(baseline survival rate and average coefficient sum) for that patient’s sex and ethnicity.
Coefficient Sum Calculation (C)
Men
White
Untreated: (ln(Age) * 12.344) + (ln(TC) * 11.853) + ((ln(Age * ln(TC)) * -2.664) + (ln(HDL) * 7.990) + ((ln(Age) * ln(HDL)) * 1.769) + (ln(SBP) * 1.764) + (Smoker * 7.837) + ((ln(Age) *
Smoker) * -1.795) + (Diabetes * .658) = C

Treated: (ln(Age) * 12.344) + (ln(TC) * 11.853) + ((ln(Age * ln(TC)) * -2.664) + (ln(HDL) * 7.990) + ((ln(Age) * ln(HDL)) * 1.769) + (ln(SBP) * 1.797) + (Smoker * 7.837) + ((ln(Age) *
Smoker) * -1.795) + (Diabetes * .658) = C

African American
Untreated: (ln(Age) * 2.469) + (ln(TC) * .302) + (ln(HDL) * -.307) + (ln(SBP) * 1.809) +
(Smoker * .549) + (Diabetes * .645) = C

Treated: (ln(Age) * 2.469) + (ln(TC) * .302) + (ln(HDL) * -.307) + (ln(SBP) * 1.916) + (Smoker *
.549) + (Diabetes * .645) = C

Women
White
Untreated: (ln(Age) * - 29.799) + ((ln(Age) * ln(Age)) * 4.884) + (ln(TC) * 13.540) + ((ln(Age) *
ln(TC)) * -3.114) + (ln(HDL) * -13.578) + ((ln(Age) * ln(HDL)) * 3.149) + (ln(SBP) * 1.957) +
(Smoker * 7.574) + ((ln(Age) * Smoker) * -1.665) + (Diabetes * .661) = C

Treated: (ln(Age) * - 29.799) + ((ln(Age) * ln(Age)) * 4.884) + (ln(TC) * 13.540) + ((ln(Age) *
ln(TC)) * -3.114) + (ln(HDL) * -13.578) + ((ln(Age) * ln(HDL)) * 3.149) + (ln(SBP) * 2.019) +
(Smoker * 7.574) + ((ln(Age) * Smoker) * -1.665) + (Diabetes * .661) = C

African American
Untreated: (ln(Age) * 17.114) + (ln(TC) * .940) + (ln(HDL) * -18.920) + ((ln(Age) * ln(HDL)) *
4.475) + (ln(SBP) * 27.820) + ((ln(Age) * ln(SBP)) * -6.087) + (Smoker * .691) + (Diabetes * .874)
=C

Treated: (ln(Age) * 17.114) + (ln(TC) * .940) + (ln(HDL) * -18.920) + ((ln(Age) * ln(HDL)) *
4.475) + (ln(SBP) * 29.291) + ((ln(Age) * ln(SBP)) * -6.432) + (Smoker * .691) + (Diabetes * .874)
=C
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10-Year ASCVD Risk Percentage Calculation
Basic Formula:
1 – Baseline Survival Ratee^(Patient Coefficient Sum – Average Coefficient Sum) = % Risk
Men
White
1 – 0.9144e^(C – 61.68) = % Risk
African American
1 – 0.8954e^(C – 19.54) = % Risk
Women
White
1 – 0.9665e^(C + 29.18) = % Risk
African American
1 – 0.9533e^(C – 86.61) = % Risk
Algorithm adapted from Goff et al. (2014)

105

APPENDIX C: MSLS COGNITIVE BATTERY AND FACTOR ANALYZED COGNITIVE
DOMAINS
Table 16. Descriptions of Cognitive Tests for Each Cognitive Domain
Composite/
Tests included
Verbal Episodic Memory

Cognitive Ability Measured

Logical Memory-Immediate Recall a

Immediate memory, verbal

Logical Memory-Delayed Recall a

Delayed Memory, verbal

Hopkins Verbal Learning Test

Verbal learning and memory

Visual-Spatial Organization/Memory
Visual Reproductions-Immediate Recall a
Visual Reproductions-Delayed Recall
Matrix Reasoning b
Block Design

a

Immediate recall, visual memory and visual spatial problem solving
Delayed recall, visual memory and visual spatial problem solving
Abstract reasoning and pattern recognition

c

Visual-spatial perception, organization

Object Assembly

c

Speed of visual-spatial organization

Hooper Visual Organization

Visual-spatial organization, some demands on executive function

Scanning and Tracking
Trail Making A d
Trail Making B

Visual scanning and tracking; concentration and attention

d

Trails A plus demands on executive function abilities

Digit Symbol Substitution

c

Symbol Search b

Psychomotor performance
Visual processing speed

Working Memory
Digit Span Forward c
Digit Span Backward

Attention and concentration
c

Letter-Number Sequence

Attention, concentration, and working memory
b

Controlled Oral Word Associations

Information processing while holding information in memory
Verbal fluency and executive function

Executive Function
Trail Making B d

Trails A plus demands on executive function abilities

Controlled Oral Word Associations
Verbal fluency and executive function
a Origin Wechsler Memory Scale-Revised
b Origin Wechsler Adult Intelligence Scale III
c Origin Wechsler Adult Intelligence Scale
d Origin Halstead-Reitan Neuropsychological Test Battery
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APPENDIX D: ADDITIONAL FIGURES FOR CVRFS AND COGNITIVE COMPOSITE
ANALYSES
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Cardiovascular Risk Factor Scale

Figure 14. CVRFS Score and Verbal Memory
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Figure 15. CVRFS Score and Visual Organization/Memory
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Figure 16. CVRFS Score and Scanning/Tracking
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Figure 17. CVRFS Score and Working Memory
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Figure 18. CVRFS Score and Executive Function
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